Koralee Mary Chaisson

AUTEUR DE LA THÈSE / AUTHOR OF THESIS

M.Sc. (Microbiology and Immunology)

GRADE / DEGREE

Department of Biochemistry, Microbiology and Immunology

FACULTÉ ÉCOLE, DEPARTEMENT / FACULTY, SCHOOL, DEPARTMENT

Interferon Regulatory Factor-3 Activation in Adenovirus Infection

TITRE DE LA THÈSE / TITLE OF THESIS

Dr. Robin Parks

DIRECTEUR (DIRECTRICE) DE LA THÈSE / THESIS SUPERVISOR

CO-DIRECTEUR (CO-DIRECTRICE) DE LA THÈSE / THESIS CO-SUPERVISOR

EXAMINATEURS (EXAMINATRICES) DE LA THÈSE / THESIS EXAMINERS

Dr. C. Addison

Dr. A. Kumar

Gary W. Slater

Le Doyen de la Faculté des études supérieures et postdoctorales / Dean of the Faculty of Graduate and Postdoctoral Studies

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Interferon Regulatory Factor-3 Activation in Adenovirus Infection

by

Koralee Chaisson

Department of Biochemistry, Microbiology, and Immunology

Submitted in partial fulfillment

of the requirements for the degree of

Master of Science

Faculty of Graduate Studies

The University of Ottawa

Ottawa, ON

March 2007

THE UNIVERSITY OF OTTAWA
ABSTRACT

Adenovirus (Ad) infection is accompanied by an early inflammatory response that is stimulated by the binding and/or entry of the Ad capsid to the cell. Several studies have linked NF-κB to the activation of pro-inflammatory cytokines and chemokines early in Ad infection, however, for many other viruses, another key transcription factor, Interferon Regulatory Factor 3 (IRF-3), also acts early in viral infection. We sought to determine if IRF-3 is activated upon Ad infection, and to examine its importance in establishing an anti-viral state in Ad-infected cells. Our data suggests that wtAd5 infection results in phosphorylation of IRF-3 on a novel amino acid residue, and this event is dependent on virus replication. Moreover, IRF-3 is an important transcription factor for induction of RANTES expression in wtAd5-infected cells. Taken together, these data suggest that IRF-3 activation in response to Ad DNA replication is important in establishing an anti-viral state within the infected cell.
Acknowledgements:

The following thesis, while an individual work, benefited from the insights and directions of several people. First, my supervisor Dr. Robin Parks, provided instructive comments and evaluation and continued to challenge, inspire, and encourage me at every stage in the thesis process. My thesis committee, Dr. Jonathan Angel and Dr. John Bell each provided individual insights that guided my thinking, greatly improving the finished product. In addition, Joel Ross, Bobby Lanthier, Kathy Poulin, Rob Meulenbroek, and Karen Powell – fellow members of the Parks lab – were always available for assistance and support and were a pleasure to work with. I am very thankful for the friendships created with these genuinely wonderful people.

In addition to technical and instrumental assistance above, I received equally important assistance from family and friends. My soon-to-be husband Michael Berghout provided constant support and encouragement throughout the thesis process. My parents Dave and Klara Chaisson instilled in me, from an early age, the desire to dream big and reach high, and continue to be my biggest fans. Finally I wish to thank my friends Jodi Van’t Foort and Lyndsey Benvie as well as my sisters Laura, Sarah, Susie, and Carolyn for keeping me in their prayers and showing me the most important things in life.
Chapter 1: Introduction
1.1 Literature Review
   I. Adenovirus
      i. Adenovirus structure and genetics
      ii. Ad pathogenicity and disease
      iii. Ad vectors
      iv. Ad vectors: efficacy and safety
   II. Innate Immune Response to Viral Infection
      i. Pathogen recognition: the Toll-like Receptors
      ii. Signaling cascades and effector cells of the innate response
   III. Innate Immune Response to Ad
      i. Immune cell response
      ii. Non-immune cell response
      iii. Cell entry
      iv. Signal transduction
   IV. Interferon Regulatory Factor 3
      i. IRF-3 signaling pathway
         i.a.) C-terminal phosphorylation
         i.b.) N-terminal phosphorylation
      ii. Virally-induced IRF-3 activation
      iii. IFNs and viral resistance
      iv. RANTES expression

1.2 Objective
1.3 Hypothesis
1.4 Approach
1.5 Rationale

Chapter 2: Materials and Methods
   Cell culture and viral infections
   IRF-3 plasmid constructs and mutagenesis
   RANTES plasmid constructs and mutagenesis
   Transient transfections
   Immunoblot analysis
   Phosphatase treatment
   Luciferase assays
Chapter 3: Results

IRF-3 is phosphorylated rapidly after VSV infection and late after wtAd5 infection
WtAd5 immunomodulatory genes affect IRF-3 phosphorylation
WtAd5-induced IRF-3 phosphorylation is replication-dependent
The primary target for wtAd5-induced phosphorylation is a novel residue(s)
RANTES induced after wtAd5 infection occurs late and is replication-dependent
Full induction of RANTES expression after wtAd5 infection is dependent on IRF-3
Over-expression of phosphorylation-mutant IRF-3 reduces wtAd5-mediated RANTES induction

Chapter 4: Discussion

WtAd5-induced IRF-3 phosphorylation
WtAd5 immunomodulatory genes interfere with IRF-3 phosphorylation
WtAd5-induced IRF-3 phosphorylation is dependent on viral replication
Primary target for wtAd5-induced phosphorylation is a novel residue(s)
WtAd5-induced RANTES expression occurs late and is replication-dependent
Future directions
Recent developments
Conclusions

References

Appendix A: Reagents
Appendix B: Plasmids
Appendix C: Published Manuscript
FSGS-associated α-actinin-4 (K256E) impairs cytoskeletal dynamics in podocytes.
### List of Abbreviations:

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ad</td>
<td>Adenovirus (Ad5 refers to serotype 5)</td>
</tr>
<tr>
<td>Ad5ts36</td>
<td>Temperature Sensitive Ad5</td>
</tr>
<tr>
<td>ARD</td>
<td>Acute Respiratory Disease</td>
</tr>
<tr>
<td>ATF-2</td>
<td>Activating Transcription Factor 2</td>
</tr>
<tr>
<td>BMDC</td>
<td>Bone Marrow Derived Dendritic Cell</td>
</tr>
<tr>
<td>BMMO</td>
<td>Bone Marrow Derived Macrophage</td>
</tr>
<tr>
<td>BZIP</td>
<td>Basic Leucine Zipper</td>
</tr>
<tr>
<td>CAR</td>
<td>Coxsackie Adenovirus Receptor</td>
</tr>
<tr>
<td>CBP</td>
<td>CREB-Binding Protein</td>
</tr>
<tr>
<td>CCR5</td>
<td>Chemokine (C-C motif) Receptor 5</td>
</tr>
<tr>
<td>CD28RE</td>
<td>CD28 Response Element</td>
</tr>
<tr>
<td>ChIP</td>
<td>Chromatin Immunoprecipitation</td>
</tr>
<tr>
<td>CIP</td>
<td>Calf Intestinal Phosphatase</td>
</tr>
<tr>
<td>CMV</td>
<td>Cytomegalovirus</td>
</tr>
<tr>
<td>CREB</td>
<td>cAMP Response Element Binding</td>
</tr>
<tr>
<td>CTL</td>
<td>Cytotoxic T Lymphocyte</td>
</tr>
<tr>
<td>DC</td>
<td>Dendritic Cell</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco Modified Eagle Medium</td>
</tr>
<tr>
<td>DNA-PK</td>
<td>DNA Protein Kinase</td>
</tr>
<tr>
<td>DsRNA</td>
<td>Double Stranded RNA</td>
</tr>
<tr>
<td>E1</td>
<td>Early gene region 1</td>
</tr>
<tr>
<td>E3</td>
<td>Early gene region 3</td>
</tr>
<tr>
<td>ΔE1Ad, E1(Δ)Ad</td>
<td>E1-deleted Ad</td>
</tr>
<tr>
<td>ΔE3Ad</td>
<td>E3-deleted Ad</td>
</tr>
<tr>
<td>ERK</td>
<td>Extracellular Signal-Related Kinase</td>
</tr>
<tr>
<td>FgAd</td>
<td>First-Generation Ad</td>
</tr>
<tr>
<td>GM-CSF</td>
<td>Granulocyte Macrophage Colony Stimulating Factor</td>
</tr>
<tr>
<td>HdAd</td>
<td>Helper-Dependent Ad</td>
</tr>
<tr>
<td>HMG-I/Y</td>
<td>High Mobility Group -I/Y</td>
</tr>
<tr>
<td>HSV</td>
<td>Herpes Simplex Virus</td>
</tr>
<tr>
<td>ICAM-1</td>
<td>Intracellular Adhesion Molecule 1</td>
</tr>
<tr>
<td>ICSBP</td>
<td>Interferon Consensus Sequence-Binding Protein</td>
</tr>
<tr>
<td>IFN</td>
<td>Interferon</td>
</tr>
<tr>
<td>IKKe</td>
<td>Inhibitor of κB Kinase ε</td>
</tr>
<tr>
<td>IL</td>
<td>Interleukin</td>
</tr>
<tr>
<td>IP-10</td>
<td>Interferon Induced Protein 10</td>
</tr>
<tr>
<td>IRF</td>
<td>Interferon Regulatory Factor</td>
</tr>
<tr>
<td>ISG</td>
<td>Interferon-Stimulated Gene</td>
</tr>
<tr>
<td>ISGF3γ</td>
<td>Interferon-Stimulated Gene Factor 3γ</td>
</tr>
<tr>
<td>ISRE</td>
<td>Interferon-Stimulated Response Element</td>
</tr>
<tr>
<td>ITR</td>
<td>Inverted Terminal Repeats</td>
</tr>
<tr>
<td>JAK/STAT</td>
<td>Janus-Activated Kinase/</td>
</tr>
<tr>
<td>JNK</td>
<td>c-Jun NH₂-Terminal Kinase</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>LPS</td>
<td>Lipopolysaccharide</td>
</tr>
<tr>
<td>LRR</td>
<td>Leucine Rich Repeat</td>
</tr>
<tr>
<td>MAPK</td>
<td>Mitogen-Activated Protein Kinase</td>
</tr>
<tr>
<td>MCP-1</td>
<td>Monocyte Chemoattractant Protein 1</td>
</tr>
<tr>
<td>MEM</td>
<td>Modified Eagle Medium</td>
</tr>
<tr>
<td>MEF</td>
<td>Mouse Embryonic Fibroblast</td>
</tr>
<tr>
<td>MeV</td>
<td>Measles Virus</td>
</tr>
<tr>
<td>MIP-2</td>
<td>Macrophage Inflammatory Protein 2</td>
</tr>
<tr>
<td>MOI</td>
<td>Multiplicity of Infection</td>
</tr>
<tr>
<td>MyD88</td>
<td>Myeloid Differentiation Marker 88</td>
</tr>
<tr>
<td>Mx</td>
<td>Mxyovirus Resistance (protein)</td>
</tr>
<tr>
<td>NDV</td>
<td>Newcastle Disease Virus</td>
</tr>
<tr>
<td>NF-AT</td>
<td>Nuclear Factor of Activated T cells</td>
</tr>
<tr>
<td>NF-IL-6</td>
<td>Nuclear Factor of Interleukin-6</td>
</tr>
<tr>
<td>NF-κB</td>
<td>Nuclear Factor-κB</td>
</tr>
<tr>
<td>NK</td>
<td>Natural Killer (cells)</td>
</tr>
<tr>
<td>OAS</td>
<td>2', 5'-Oligoadenylate Synthetase</td>
</tr>
<tr>
<td>p125FAK</td>
<td>Focal Adhesion Kinase</td>
</tr>
<tr>
<td>p130CAK</td>
<td>Crk-Associated Kinase</td>
</tr>
<tr>
<td>PAMP</td>
<td>Pathogen-Associated Molecular Pattern</td>
</tr>
<tr>
<td>PBMC</td>
<td>Peripheral Blood Mononuclear Cells</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate Buffered Saline</td>
</tr>
<tr>
<td>PCR</td>
<td>Polymerase Chain Reaction</td>
</tr>
<tr>
<td>PFU</td>
<td>Plaque Forming Units</td>
</tr>
<tr>
<td>P13K</td>
<td>Phosphoinositide-3-OH Kinase</td>
</tr>
<tr>
<td>PKA</td>
<td>Protein Kinase A</td>
</tr>
<tr>
<td>PKR</td>
<td>Protein Kinase R</td>
</tr>
<tr>
<td>PRD</td>
<td>Positive Regulatory Domain</td>
</tr>
<tr>
<td>PRR</td>
<td>Pattern Recognition Receptor</td>
</tr>
<tr>
<td>RANTES</td>
<td>Regulated on Activation, Normal T-cell Expressed and Secreted</td>
</tr>
<tr>
<td>RFLAT-1</td>
<td>RANTES Factor of Late Activation of T-Lymphocytes-1</td>
</tr>
<tr>
<td>RGD motif</td>
<td>Arginine-Glycine-Aspartic Acid</td>
</tr>
<tr>
<td>RID</td>
<td>Receptor Internalization and Degradation (complex)</td>
</tr>
<tr>
<td>RIG-I</td>
<td>Retinoic Acid Inducible Gene-I</td>
</tr>
<tr>
<td>RIPA</td>
<td>RadioImmunoPrecipitation Assay (buffer)</td>
</tr>
<tr>
<td>RSV</td>
<td>Respiratory Syncytial Virus</td>
</tr>
<tr>
<td>RT-PCR</td>
<td>Reverse Transcription Polymerase Chain Reaction</td>
</tr>
<tr>
<td>RV</td>
<td>Rabies Virus</td>
</tr>
<tr>
<td>SARM</td>
<td>SAM and ARM-Containing Protein</td>
</tr>
<tr>
<td>SDS-PAGE</td>
<td>Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis</td>
</tr>
<tr>
<td>SeV</td>
<td>Sendai Virus</td>
</tr>
<tr>
<td>SR</td>
<td>Serine/Arginine Rich (family of splicing proteins)</td>
</tr>
<tr>
<td>TANK</td>
<td>TRAF-Associated NF-κB Activator</td>
</tr>
<tr>
<td>TBK-1</td>
<td>TANK Binding Kinase 1</td>
</tr>
<tr>
<td>TBS-T</td>
<td>Tris Buffered Saline (with Tween)</td>
</tr>
<tr>
<td>Th-1</td>
<td>Helper T cell Type 1</td>
</tr>
<tr>
<td>TIR</td>
<td>Toll/IL-1R</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Full Name</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------</td>
</tr>
<tr>
<td>TIRAP</td>
<td>TIR-Containing Adaptor Protein</td>
</tr>
<tr>
<td>TLR</td>
<td>Toll-Like Receptor</td>
</tr>
<tr>
<td>TNF-α</td>
<td>Tumor Necrosis Factor α</td>
</tr>
<tr>
<td>TRAF</td>
<td>TNF Receptor Associated Receptor</td>
</tr>
<tr>
<td>TRAIL</td>
<td>TNF-Related Apoptosis-Inducing Ligand</td>
</tr>
<tr>
<td>TRAM</td>
<td>TRIF-Related Adaptor Molecule</td>
</tr>
<tr>
<td>TRIF</td>
<td>TIR-Domain-Containing Adaptor Protein Inducing IFNβ</td>
</tr>
<tr>
<td>VAK</td>
<td>Viral Activating Kinase</td>
</tr>
<tr>
<td>VSV</td>
<td>Vesicular Stomatitis Virus</td>
</tr>
<tr>
<td>wtAd5</td>
<td>Wild-type Ad5</td>
</tr>
</tbody>
</table>
### List of Figures:

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Schematic representation of Ad virion cross-section</td>
<td>3</td>
</tr>
<tr>
<td>2</td>
<td>TLR-virus interactions</td>
<td>10</td>
</tr>
<tr>
<td>3</td>
<td>The innate immune response to adenovirus vectors</td>
<td>13</td>
</tr>
<tr>
<td>4</td>
<td>Schematic representation of human IRF-3</td>
<td>20</td>
</tr>
<tr>
<td>5</td>
<td>Basic schematic representation of IRF-3 activation pathway in response to RNA viruses VSV and SeV</td>
<td>22</td>
</tr>
<tr>
<td>6</td>
<td>VSV and wtAd5-induced IRF-3 phosphorylation</td>
<td>37</td>
</tr>
<tr>
<td>7</td>
<td>Phosphatase sensitivity of wtAd5-induced IRF-3 phosphorylation</td>
<td>40</td>
</tr>
<tr>
<td>8</td>
<td>IRF-3 phosphorylation in ΔE3Ad infection at increasing MOI</td>
<td>41</td>
</tr>
<tr>
<td>9</td>
<td>IRF-3 phosphorylation in temperature sensitive Ad5ts36 infection</td>
<td>43</td>
</tr>
<tr>
<td>10</td>
<td>IRF-3 phosphorylation in ΔE1Ad infection at increasing MOI</td>
<td>45</td>
</tr>
<tr>
<td>11</td>
<td>Mutant IRF-3 plasmids used to determine phosphorylation site(s) in wtAd5 infection</td>
<td>47</td>
</tr>
<tr>
<td>12</td>
<td>Analysis of wtAd5-induced IRF-3 phosphorylation</td>
<td>48</td>
</tr>
<tr>
<td>13</td>
<td>WtAd5-induced RANTES expression</td>
<td>50</td>
</tr>
<tr>
<td>14</td>
<td>Optimal MOI for wtAd5-induced RANTES expression</td>
<td>51</td>
</tr>
<tr>
<td>15</td>
<td>ΔE1Ad-induced RANTES expression</td>
<td>53</td>
</tr>
<tr>
<td>16</td>
<td>Contribution of IRF-3 and NF-κB in wtAd5-induced RANTES expression as observed using fragments of a deletional mutant of the human RANTES promotor.</td>
<td>55</td>
</tr>
<tr>
<td>17</td>
<td>Contribution of IRF-3 and NF-κB in wtAd5-induced RANTES expression as observed using human RANTES promotor constructs containing point mutations within IRF-3 and NF-κB binding sites.</td>
<td>56</td>
</tr>
<tr>
<td>18</td>
<td>IRF-3 activation in wtAd5-induced RANTES expression</td>
<td>58</td>
</tr>
</tbody>
</table>

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Chapter 1: INTRODUCTION

Adenovirus infection, both naturally and upon delivery of gene therapy vectors, is accompanied by a strong inflammatory response known as the innate immune response. To date, the innate immune response to Ad is not completely understood. Recent reemergence of Ad-induced acute respiratory disease (ARD) in confined populations, as well as the prevalence of other Ad-related diseases in children, the elderly, and immuno-compromised individuals, demonstrate the need for an Ad vaccine and an effective antiviral compound or form of immunotherapy against Ad. Conversely, in recent years, Ad vectors have become popular gene transfer vehicles in multiple gene therapy studies, yet the delivery of high doses of these vectors results in significant acute inflammation that reduces the effectiveness of the vector. Thus, a current emphasis in Ad gene therapy research is to determine the mechanisms by which Ad induces the early inflammatory response, and to modify Ad vectors accordingly in order to eliminate this very dangerous and even lethal problem. In order to elucidate novel methods to combat severe Ad diseases and innovative strategies for the development of nontoxic therapeutic Ad vectors, an improved understanding of the molecular mechanisms and signaling pathways that shape the immune response to Ad is of great importance.
1.1 Literature Review

I. Adenovirus

i. Adenovirus structure and genetics

Adenovirus (Ad) was first isolated from human adenoid cells by Rowe et al. in 1953 (1). Since that time, at least 50 other distinct human Ad serotypes have been identified (2). These serotypes are classified into 6 subgroups (A-F), based on DNA homology, genomic organization, hemagglutination properties, and oncogenicity in rodents (3). The Ad virion is non-enveloped and formed of an icosahedral-shaped protein shell called the capsid. The capsid is composed of 3 major structural proteins, hexon, penton, and fiber, and several other more minor proteins. The surface of the capsid is made up of 240 hexon protein trimers, which together form the 20 triangular faces of the icosahedron. Located at each of the 12 vertices is a penton base protein, from which a fiber protein extends (Fig. 1) (4-8). The fiber protein is used for binding to the host receptor CAR (coxsackie adenovirus receptor). With the exception of subgroup B, CAR is used for attachment and entry of all human Ad groups (9-12). Within the capsid lies a DNA-protein core complex containing a 30- to 40-kb genome of linear double-stranded (ds) DNA (6, 13). The Ad genome is separated into early (E) genes and late (L) genes. The early genes are the first to be transcribed, and they encode proteins that are involved in the control of viral DNA synthesis (E2A and B), transcription (E1A), transport of mRNAs to the cytoplasm (E1B, E4Orf6), and immunoregulation (E3, E1B, E4). The late genes are primarily structural genes and encode the proteins that form the Ad capsid (14).

The “early” and “late” phases of the Ad replication cycle are separated by the onset of viral replication. However, the functional distinction between “early” and “late” events is
Figure 1. Schematic representation Ad virion cross-section.
(Rux and Burnett, 2004 (6). Used with permission)
often blurred, as early genes continue to be expressed at late times after infection, and the promoter which controls the expression of the major late transcription unit directs a low level of transcription early after infection (14). In HeLa cells - most often used for Ad studies since Ads grow in them rapidly and to high yield - the “early” phase lasts for about 5-6 hr after which viral DNA is first detected. The “late” phase of Ad replication comes with the onset of DNA replication, and after 20-24 hr, approximately $10^4$ progeny virus particles/cell have been produced and the infectious cycle is completed (14, 15).

**ii. Ad pathogenicity and disease**

Human Ad is a common pathogen, and the diseases caused by Ad are varied. The degree of Ad-induced disease differs between serotypes (2), and each Ad group appears to preferentially infect different tissue groups (5). For example, group B Ads are primarily responsible for lower respiratory tract and urinary tract infections, group A and D Ads often cause diseases in the intestine, Ads 40 and 41 from group F are enteric and cause diarrhea in small children, and Ads 8, 19, and 37 of group D cause keratoconjunctivitis in the eye (5). The most common Ad diseases, however, are infections of the upper respiratory tract. These are caused primarily by group C Ads 2 and 5, which are the most extensively studied serotypes of all human Ad (2, 5, 6, 13). Ads replicate best in epithelial cells and very poorly in lymphocytes, but have also been known to target heart tissue (5, 16, 17). In fact, Ads cause 17% of pediatric and 4% of adult cases of viral myocarditis (18), and Ad-induced myocarditis has, in turn, been linked to sudden infant death syndrome (SIDS) (19).

In most patients, Ad causes relatively minor, self-limiting diseases. However, among pediatric and geriatric populations, as well as in immunocompromised individuals (such as bone marrow and organ transplant recipients and patients affected with acquired immune
deficiency syndrome (AIDS)), Ad infections can be severe and life threatening, most especially in the lung and liver (5). Ads can be very virulent in children, as they are known to cause 8% of all respiratory tract infections and are responsible for 5% of the overall number of infections observed in pediatric populations (20). Ad infection among children often leads to bronchitis, bronchiolitis, or pneumonia, and latent Ad infection can contribute to asthma chronicity (20, 21). In confined populations including day-care centers, nursing homes, and most especially military training venues, acute respiratory disease (ARD) (caused by Ads 4, 7 and to a lesser extent Ad21), is a growing problem (5, 22). Until recently, mandatory vaccination of new military recruits with an oral enteric-coated live Ad vaccine reduced the rate of ARD. Unfortunately, this vaccine is no longer available and there has been a reemergence of Ad-induced ARD back to pre-vaccination levels (5, 23-25). In addition, therapy for serious and severe Ad infection remains unsatisfactory, as no studies show statistical proof of efficacy for any kind of immunotherapy or antiviral compound. Hence, there exists an obvious need for an increase in study directed toward the biology of wild-type Ad infection, with a specific focus on achieving a greater understanding of the immune response to Ad. An improved understanding of Ad-host interactions may elucidate novel methods to combat severe Ad disease and eliminate the increasingly widespread problem of Ad-induced ARD.

iii. Ad vectors

In recent years, a major emphasis in Ad research has been directed towards the use of Ad5-based vectors as vehicles for gene delivery in gene therapy studies (see (26) for review). There are several reasons why Ad is an excellent vector choice, making it a widely popular vehicle for gene transfer. Ad is well characterized both biochemically and
genetically, it is easy to manipulate, and can be grown to high titers (27). More importantly, Ad is able to transduce a wide array of cell types in a cell cycle independent manner, and the deletion of non-essential protein coding regions from its genome increases cloning capacity by allowing for the insertion of foreign DNA (28). For example, first-generation Ad vectors (fgAd), are deleted of the E1 and E3 genes and can accommodate up to 8 kb of therapeutic DNA (29). Second-generation Ad vectors are also deleted of E1 and E3 genes, but contain other deletions or inactivated E2 or E4 genes (27). A more recent vector strategy further increases cloning capacity as it involves the creation of vectors deleted of all viral sequences with the exception of those required for viral DNA replication and packaging (i.e. the viral ITRs (inverted terminal repeats) and packaging elements). These vectors, known as helper-dependent Ads (hdAd), are created through dual infection with a complementing helper virus that provides the necessary proteins in trans for replication and packaging of all other viral proteins. Cre-mediated removal of the packaging element from the helper virus prevents its encapsulation into virions and this ensures the recovery of high titer, relatively pure hdAd (27, 30, 31).

iv. Ad vectors: efficacy and safety

First-generation Ad vectors are frequently used as all-purpose expression vectors and as viral vaccines. They have also been used in gene therapy applications, but have performed relatively poorly during pre-clinical and clinical studies due to fgAd-induced innate (early) and adaptive (late) immune responses that work to eliminate the vectors, thereby making stable (long term) transgene expression unachievable (32-37). Early inflammation (innate immune response) following Ad infection is caused by the detection of the infecting virion proteins injected at the time of treatment, while later inflammation
(adaptive immune response) is associated with the expression of viral proteins from the Ad vector backbone (30, 34, 38). Unfortunately, the intensity of these in vivo responses not only limits the efficacy of the vectors, but also the safety of those receiving the treatment (13, 28). Significant morbidity and major damage to healthy tissue are possible additional hazards faced by each recipient of gene therapy (39, 40). In extreme cases, death can occur (41).

Second-generation Ad vectors with deleted or inactivated E2 genes persist longer in transduced cells and are associated with a reduced early inflammatory response (42-44). Vectors with deleted or inactivated E4 genes also cause decreased early inflammatory response, but unfortunately have a significantly reduced time frame of transgene expression (30, 45-48). Relative to first- and second-generation Ad vectors, however, hdAd vectors have excellent expression characteristics, and can provide high levels of transgene expression for considerably longer periods of time. This is achievable since hdAd do not elicit the later (adaptive) inflammatory response because they are deleted of all viral coding sequences (30). However, although the problem of late inflammation appears to be eliminated with the use of hdAd, the delivery of high doses of hdAd required in most gene therapy studies can lead to a very dangerous and even lethal early inflammatory response, as observed in non-human primates (49). Therefore, the current emphasis in Ad gene therapy research is to determine the mechanisms by which Ad induces the early inflammatory response, and to modify Ad vectors accordingly in order to eliminate this problem.

II. Innate Immune Response to Viral Infection

i. Pathogen recognition: the Toll-like Receptors

The innate immune response is a host's first line of defense against invading pathogens. Working via immune effector cell recruitment and complicated signaling
cascades, it allows for the rapid detection, attenuation, and eradication of infection (50). In order to trigger the cascade of events necessary for the elimination of infection, the target cell (or resident macrophage) must first be able to detect the invading pathogen. Therefore, the innate immune response begins with one of its principle functions: pathogen recognition which occurs through a number of different pattern recognition receptors (PRRs) located in both intracellular and extracellular compartments (51). Toll-like receptors (TLRs), the best-studied family of PRRs, are type I transmembrane receptors that recognize invariant molecular structures shared by pathogens of various origin. These structures are also known as pathogen associated molecular patterns (PAMPs) (52, 53). There are 11 known TLRs in humans (TLR1-11) however the functionality of human TLR11 has yet to be determined (54). Although TLRs were originally thought to be strictly extracellular transmembrane receptors, certain TLRs (TLR3, 7/8, 9) are localized to intracellular compartments, particularly in the endoplasmic reticulum, and within endosomes of certain subsets of cells (55-57).

Each TLR has three distinct domains: an extracellular domain characterized by leucine-rich repeats (LRRs), a single transmembrane domain, and an intracellular signaling domain known as the Toll/IL-1R (TIR) domain. All TLRs share similar extracellular LRRs, however, each recognizes a different microbial signature (58). In fact, each TLR has many ligands, both exogenous and endogenous, indicating a potential for each TLR to contain multiple binding sites, and perhaps also to act as an integrator of signaling with other receptors. In this way, it may not be necessary for the TLRs to bind directly to each ligand, explaining why in most cases, direct binding between a TLR and a putative microbial ligand has not been demonstrated (58, 59). The intracellular TIR domain is responsible for the recruitment of signaling molecules to activate downstream signaling pathways that lead to
the activation of transcription factor NF-κB (nuclear factor-κB) and the IRFs (interferon regulatory factors) that activate the immune response through the induction of cytokines and interferons (IFNs) (58). With the exception of TLR3, all TLRs transduce signals through the adaptor protein MyD88 (myeloid differentiation marker 88). Four other adaptor proteins – TIRAP (TIR-containing adaptor protein), TRIF (TIR-domain-containing adaptor protein inducing IFNβ), TRAM (TRIF-related adaptor molecule), SARM (SAM and ARM-containing protein) – are also used differentially by the TLRs (59).

Although studies centering on innate immunity and TLRs were initially focused on bacterial models, it is becoming more evident that viral recognition also occurs through TLRs (13). Specifically, TLR2, 3, 4, 7/8, and 9 are involved in the antiviral innate immune response (Fig. 2) (60). These TLRs interact with various viral components: envelope glycoproteins (TLR2 and 4), viral double-stranded RNA (dsRNA) (TLR3), single-stranded RNA (ssRNA) (TLR7 and 8), and CpG motifs contained in viral DNA (TLR9). TLR3 and TLR9, which are localized intracellularly, are also in the ideal position for mediating the intracellular recognition of viral particles (13, 59, 60).

ii. Signaling cascades and the effector cells of the innate response

Following viral particle recognition by innate receptors, a cascade of events is triggered in an effort to limit and eradicate infection. One of the first events to take place is the activation of transcription factor NF-κB via signal transduction through the mitogen-associated protein kinases (MAPKs) including extracellular signal-related kinases (ERK), p38 kinases (p38), and the c-Jun NH2-terminal kinases (JNK), which ultimately results in the transcription of host cytokine and chemokine genes (51, 61). These genes confer local
Figure 2. TLR-virus interactions.
(Finberg and Kurt-Jones, 2004 (60). Used with permission)
Human Cytomegalovirus (HCMV)
Mouse Cytomegalovirus (MCMV)
Measles virus (Rubella)
Lymphocytic Choriomeningitis Virus (LCMV)

Herpes Simplex Viruses
HSV-1
HSV-2

Respiratory syncytial virus (RSV)
Mouse mammary tumor virus (MMTV)
Coxsackie virus

Influenza virus
Vesicular stomatitis virus (VSV)
Reovirus
Rotavirus
control of infection and recruit different types of effector leukocytes (granulocytes, monocytes/macrophages), natural killer (NK) cells, and NK T-cells to the site of infection. As phagocytes, monocytes/macrophages act to ingest and destroy viral particles, but also secrete antiviral cytokines and participate in antigen presentation required to prime the adaptive immune response (62, 63). Granulocytes (neutrophils) recruited to the site of infection are also an important source of cytokines that have antiviral activity and amplify the immune response (13). NK cells, large granular lymphocytes, perform seven cytolytic functions that restrain viral infections, and along with NK T cells, secrete IFN (interferon)-γ which is essential for the development of helper T cell type 1 (Th-1)-dominant adaptive immune responses (64).

III. Innate Immune Response to Ad

To date, most of the studies examining the immunological responses to Ad are based on in vivo and in vitro studies with Ad vectors (13, 50). However, several aspects of Ad vector biology differ from wild-type Ad infection. For example, Ad vectors are replication-deficient and some lack all or many viral coding sequences. Some of these viral coding regions, specifically those within the Ad E3 gene region, encode viral immunoregulatory genes that target processes essential for the survival of the virus during acute and latent infection, and this region is deleted from most gene therapy vectors (5). In addition, the titers of Ad vectors required to achieve efficient gene transfer in vivo are many folds higher than viral particle numbers observed in early wild-type Ad infection (13). Thus, studies based on characterization of immune responses to Ad vectors cannot always be accurately extrapolated to the immunological events surrounding wild-type Ad infection.
i. Immune cell response

The innate immune response to Ad vectors is dose-dependent, occurs within 24 hr of host transduction and is independent of viral or transgene transcription (Fig. 3) (13, 38). The inflammatory genes induced by Ad vectors in vivo are numerous, and include cytokines tumor necrosis factor-α (TNF-α), IL-6 (interleukin-6), IL-1β, IFN-γ, and IL-12 and chemokines IFN-γ-inducible protein-10 (IP-10), RANTES (regulated on activation, normal T-cell expressed and secreted), macrophage inflammatory protein-2 (MIP-2), MIP-1α, MIP-1β, and monocyte chemoattractant protein-1 (MCP-1) (13, 40, 65-67). Ad preferentially infects the liver after systemic and local delivery (68) so it is not surprising that within 60 minutes of Ad vector transduction in mice, the induction of multiple chemokine mRNAs can be observed in liver tissue (34). In addition, Kupffer cells (the resident macrophages of the liver) are quick to take up the vectors and in turn release TNF-α, IP-10, and RANTES (34, 66) which are together associated with leukocyte recruitment (50). Indeed, Ad vector-transduced tissues are also quickly infiltrated with neutrophils and NK cells (34, 69).

Recently, micro-array studies by Hartman et al. (70) demonstrated a potent cellular transcriptome response in murine liver samples as early as 6 hr following intravenous administration (via retro-orbital sinus) of high-titer ΔE1/E3 or ΔE1/E2b/E3 Ad vectors. In addition, transcriptome analysis revealed that the complex innate response to the Ad vectors used was very similar to that observed when mice were challenged with LPS (lipopolysaccharide). However, unique aspects of the Ad-dependent transcriptome response included the upregulation of RNA regulatory mechanisms and apoptosis-related pathways.
Figure 3. The innate immune response to Ad vectors.
Ad infection of several tissue types results in immediate stimulation of signal transduction pathways that ultimately lead to expression of pro-inflammatory cytokines (Muruve, 2004 (13). Used with permission)
Monocytes

NK Cells

Tissue Macrophage/Dendritic Cell

Leukocyte Recruitment

Chemokines Cytokines

Target Tissue

Adhesion Molecules

Endothelium

Chemokines Cytokines

Antiviral

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
and the suppression of lysosomal and endocytic genes. The TLR system, specifically TLR adaptor MyD88, was also implicated in these responses, demonstrating an important role for MyD88 as an amplifier and regulator of Ad vector immunity in vivo (70).

In lung tissue, Zsengeller et al. (71) observed that within 10 minutes after Ad vector administration there was a rapid accumulation of vector in alveolar macrophages which was associated with up-regulation of cytokines IL-6 and TNF-α, and chemokines MIP-2 and MIP-1α. Additionally, Otake et al. (66) observed the induction of RANTES in lung tissue within hr of Ad vector transduction. In vitro studies have also demonstrated that Ad vectors can stimulate the expression of cytokines and chemokines in peripheral blood mononuclear cells (PBMC) (72). Specifically, when Ad vectors were administered at a dose of 1000 PFU (plaque forming units) per cell, a minimal release of TNF-α and IL-1β, a significant increase in IL-6 and RANTES, and a steady increase in GM-CSF (granulocyte/macrophage colony stimulating factor), MIP-1α, Gro-α (an inducible neutrophil chemotactic factor), and IL-8 was observed over 96 hr (72). Furthermore, when the experiment was repeated using UV-psoralen-inactivated vector particles or empty capsids, the aforementioned response did not diminish thereby confirming the importance of the viral particle/capsid and not viral gene expression in this process (72).

ii. Non-immune cell response

Ad vectors also induce the expression of various cytokines and chemokines in non-innate cell types such as epithelial and endothelial cells (50). For example, in primary kidney epithelial cells, RANTES, IP-10, and MIP-2 are induced within 6 hr of Ad vector transduction (38). Furthermore, early induction of various chemokines including RANTES,
IP-10, and IL-8 has been observed following Ad vector transduction in HeLa cells, non-small cell lung adenocarcinoma cell line A549, and mouse insulinoma cell line TGP61 (38, 73-76). Aside from cytokine and chemokine induction, Ad vectors can also induce the expression of other genes involved in the inflammatory response. For instance, in epithelial A549 cells and endothelial cells (human umbilical vein and bone marrow macrovascular cells), Ad vectors induce the expression of leukocyte adhesion molecules ICAM-1 (intracellular adhesion molecule-1) and VCAM-1 (vascular cell adhesion molecule-1) (77, 78) that facilitate leukocyte recruitment to Ad vector-transduced tissues (79). In addition, recent micro-array analysis of ΔE1/E3Ad-transduced mouse embryonic fibroblast cell isolates (MEFs) demonstrated a similar transcriptome response to that observed in murine liver tissue upon intravenous administration of high-titer ΔE1/E3 or ΔE1/E2b/E3 Ad vectors (70, 80). This widespread gene expression program involved significant changes in the expression of genes involved in focal adhesion, tight junction, and RNA regulation in addition to TLR pathway and other innate sensing genes (80).

\[iii.\ \textit{Cell entry}\]

\textit{In vitro} and \textit{in vivo} studies have clearly demonstrated that viral capsid binding and/or entry into the cell initiate the earliest events in the innate immune response to Ad infection (13, 50). There is a good basis of understanding of the many different signaling pathways that are used by group C Ads (Ad2 and Ad5) to internalize and infect cells. However, while it is not surprising that Ad vector entry into the cell triggers the innate immune response, the impact of signal activation on host inflammation and the antiviral responses that occur during this process are poorly understood (13, 50).
In epithelial cells, group C Ad cell entry is mediated by interactions with the high affinity receptor CAR and αv-integrins (9, 81). Ad attaches to the CAR receptor through an interaction with the carboxy terminus of its fiber knob protein (9). Viral internalization occurs by receptor-mediated endocytosis through clathrin-coated vesicles. This process is mediated by a low affinity interaction between αv-integrins (αvβ3, αvβ5, αvβ1) and an RGD motif (arginine-glycine-aspartic acid) on the Ad penton base capsid protein (81, 82). Within 10 minutes of internalization, Ad penetrates the endosome in a pH-dependent manner believed to involve a conformational change in the Ad penton base protein and an interaction with αvβ3 integrins (83-85). In addition, protein VI, once exposed during capsid disassembly, has been shown to exhibit pH-independent membrane lytic activity (86). Traveling through the cytoplasm along microtubules, partially uncoated Ad virions reach the nuclear pore complex 30-40 minutes after endoplasmal escape (83, 87, 88), and entry of viral DNA into the nucleus is facilitated by the binding of hexon protein to histone H1(89). Initial cell binding of group C Ads can also be mediated by heparan sulphate glycosaminoglycans (90). In addition, studies with Ad vector infection in the monocytic cell line THP-1, demonstrate important interactions with other integrins such as αMβ2 and α4β2, indicating that in macrophages, group C Ads use different cell surface molecules for binding (91). It is possible that this property of group C Ads might also be observed in other cell types.

iv. Signal transduction

Several independent studies supported the idea that the whole Ad capsid can trigger a series of early signals initiating the inflammatory response, however, not much was known about the role played by Ad surface domains (knob, hexon, penton base). Previous studies
had suggested that CAR does not appear to be specifically necessary for signal activation by Ad vectors (75, 92, 93). In these studies CAR-ablated fiber knob mutant vectors induced similar levels of IP-10 gene expression when compared with wild-type capsid vectors (93, 94). Recently, however, Tamanini et al. (8) demonstrated that the binding of the Ad fiber knob protein to CAR on A549 cells is responsible for the induction of MAP kinases (ERK1/2 and JNK) and transcription factor NF-κB and the resulting gene transcription of different chemokines (IL-8, Gro-α, Gro-γ, RANTES, IP-10). Furthermore, when the interaction of Ad fiber to CAR was blocked in A549 cells, they did not observe any residual activation (8). Tamanini et al. (8) argue that discrepancies between studies can be explained by considering the different cell types studied (renal epithelial cells versus alveolar type II-derived cells) and the very high concentration of CAR-ablated fiber knob mutant vectors used. However, group B Ad particles that do not use CAR as a high affinity receptor (11) can still equally induce IP-10 and RANTES in epithelial cell lines (75, 93). Taken together, this data suggests that signal transduction in response to CAR binding appears to be cell-type and group specific, and has yet to be completely elucidated.

Although Tamanini et al. (8) demonstrated that other major Ad surface domains (hexon, penton base) are not involved in MAPK and NF-κB pro-inflammatory signaling, they also showed that binding of Ad penton base protein to αv integrins resulted in the activation of p125FAK (focal adhesion kinase), p130CAS (Crk-associated kinase), PI3K (p85/phosphoinositide-3-OH kinase), and PKA (protein kinase A). Indeed, integrins have been implicated in a wide array of signaling events that regulate protein kinases, growth factor receptors, and the organization of the actin skeleton (13, 50, 92, 95).
Despite an incomplete understanding of signal transduction in response to CAR binding, several in vitro studies have described steps in the signaling pathways that occur in response to infection by Ad vectors. In HeLa cells, Bruder and Kovesdi (76) demonstrated Ad vector-induced ERK signaling, and linked this event with IL-8 expression. Within 5 minutes of Ad vector transduction, they observed the activation of Raf-1 (the downstream effector of the Ras GTP (guanosine triphosphate) binding protein) followed by p42/MAPK phosphorylation 10 minutes later (76). Other studies with a mouse kidney-derived epithelial cell line (REC; renal epithelial cells) revealed the activation of p38 and ERK (but not JNK) as early as 10 minutes and persisting up to 3 hr following Ad vector transduction (93). Furthermore, the activation of these kinases was linked directly to chemokine IP-10 gene expression (93). Finally, further studies have demonstrated that within 2 hr of transduction in both REC and HeLa cells, Ad vectors can induce nuclear translocation and subsequent activation of transcription factor NF-kB, an event that is directly involved in the transcription of chemokines such as IP-10 and RANTES (74, 75). Indeed, the activation of NF-kB represents an important first step in the cascade of events controlling both innate and adaptive immunity to Ad (51, 61).

IV. Interferon Regulatory Factor 3 (IRF-3)

For many viruses, another important transcription factor involved in the innate immune response is interferon regulatory factor 3 (IRF-3) (96). Characterized by Au et al. (97), IRF-3 is a unique member of the human IRF family of transcription factors. This family is comprised of nine members (IRF-1, IRF-2, IRF-3, IRF-4, IRF-5, IRF-6, IRF-7, interferon consensus sequence-binding protein (ICSBP), and interferon-stimulated gene
factor 3γ (ISGF3γ)), each member with distinct roles in host defense against pathogens, immunomodulation, and growth control (98, 99). IRF-3 is activated in response to infection by a number of viruses including Sendai Virus (SeV), Measles Virus (MeV), Newcastle Disease Virus (NDV), Vesicular Stomatitis Virus (VSV), Respiratory Syncytial Virus (RSV), human Cytomegalovirus (CMV), and Herpes Simple Virus (HSV) type I (99-104).

i. IRF-3 signaling pathway

The IRF-3 gene encodes a 427 amino acid phosphoprotein that is constitutively expressed in all cell types and tissues (96, 105). Studies by Karpova et al. (106) have demonstrated that IRF-3 mRNA can be alternatively spliced by the SR (serine/arginine rich) family of splicing factors to form a 50 kDa splice variant known as IRF-3a. IRF-3a contains a unique 20 amino acid sequence in place of a portion of the N-terminal DNA binding domain that is lost in the splicing event (106). Like IRF-3, IRF-3a is ubiquitously expressed in all cell types and tissues. It appears as though IRF-3 mRNA splicing may be regulated in a tissue-specific manner; the highest ratio of IRF-3a to IRF-3 is found in brain tissue (107).

In its latent form in uninfected cells, IRF-3 exists in two monomeric isoforms (forms I and II) of about 55 kDa that can be resolved by SDS-PAGE (96, 101). Phosphorylation of IRF-3 can occur in four different regions; the first two regions are located within the N-terminus of the protein (residues Ser\textsuperscript{135} and Thr\textsuperscript{188}), while the second two regions are located within the C-terminus of the protein (residues Ser\textsuperscript{385}/Ser\textsuperscript{386} and Ser\textsuperscript{396}/Ser\textsuperscript{398}/Ser\textsuperscript{402}/Thr\textsuperscript{404}/Ser\textsuperscript{405}) (Fig. 4) (96). Upon viral infection, IRF-3 is phosphorylated within the C-terminus of the protein, resulting in forms III and IV, which are resolved by SDS-PAGE as more slowly migrating isoforms than forms I and II (101, 108).
Figure 4. Schematic representation of human IRF-3.
Four important regions of human IRF-3 are demonstrated: the N-terminal interferon regulatory factor (IRF) binding domain, the nuclear export sequence (NES) containing a proline-rich region (PRO), the IRF association domain, and the C-terminal signal response domain. The region between residues 128-142, 186-198, and 382-414 are expanded below the schematic to demonstrate the amino acids, in large letters, that are known to be phosphorylated by DNA-protein kinase (DNA-PK, Thr135), a member of the map kinase family (MAPK, Ser188), and a viral activating kinase (VAK, Ser385/Ser386, and Ser396/Ser398/Ser402/Thr404/Ser405). Adapted from Servant et al. 2002 (96).
DNA Binding | NES | IRF Association | Signal Response

DNA-PK: GGGSTSDTQEDILDE (135)
MKKK: GPLENPLKRLLVP (188)
VAK: GGA\text{SSL\text{N}HPLSLTS\text{D}\text{Q}KAYLQD} (385/386) (396/398) (402/404/405)
i. a.) C-terminal phosphorylation

It is widely accepted that true activation of IRF-3 occurs only when it is phosphorylated within the 385-405 amino acid C-terminal region of the protein (96, 101, 105, 109, 110), although the exact phosphorylation site within this region remains the subject of great debate (105, 108-112). In addition, the mechanism of IRF-3 activation and the identity of the viral activating kinase (VAK) responsible vary depending on the virus and the stimuli, and it is likely that multiple signaling pathways and kinases lead to activation of IRF-3 (96, 99). Recently, IKK-related kinases IKKe (Inhibitor of κB kinase ε) and TBK1 (Tank binding kinase 1) have been identified as components of the VAK responsible for C-terminal phosphorylation of IRF-3 during Sendai virus infection (113, 114).

Phosphorylation of IRF-3 by the VAK results in a conformational change in IRF-3 that exposes its DNA binding and transcriptional activation domains (96, 105, 115) thereby promoting homodimerization and binding to the IRF-3 consensus DNA binding site (96, 105, 109, 110). At the same time, this phosphorylation event is required for interaction with the histone acetyltransferase nuclear proteins CBP (CREB binding protein) and p300, which stop IRF-3 from shuttling in and out of the nucleus and enable it to remain predominately nuclear (Fig. 5) (96, 105, 109, 110, 116). Once in the nucleus, IRF-3 and CBP/p300 form a larger complex called the IFN-β enhanceosome, also consisting of the NF-κB p50/p65 heterodimer, and the b-ZIP (basic leucine zipper) proteins ATF-2 (activating transcription factor 2) and c-Jun, and all assembled on the HMG-I/Y (high mobility group- I, Y) architectural protein (117). This complex induces transcription by binding to distinct positive regulatory domains (PRD) in the type I IFN promoters (including IFN-β) and select ISRE (interferon-stimulated response element) sites in target genes (96, 105, 109, 110, 115, 118-120). Full induction...
Figure 5. Basic schematic representation of IRF-3 activation pathway in response to RNA viruses VSV and SeV. Following infection by an RNA virus such as VSV or SeV, IRF-3 is phosphorylated by a viral activating kinase (VAK). This phosphorylation causes a conformational change in IRF-3, allowing for dimerization, CBP/p300 binding, and migration to the nucleus. Here, activated IRF-3 is retained and the IFN-β enhanceosome is formed from dimerized IRF-3 and CBP/p300 (as well as the NF-κB p50/p65 heterodimer, ATF-2, and c-Jun). The IFN-β enhanceosome complex induces transcription IFN-β, and subsequent IFN stimulated genes (ISGs). Activated IRF-3 can also directly lead to the induction of pro-inflammatory chemokines (RANTES, IP-10) and cytokines (IL-15) as well as ISGs such as ISG56. IRF-3 is rapidly degraded following activation.
IFN enhanceosome

IFN stimulated genes

Sendai
VSV

VAK

IRF-3

IRF-3

IRF-3

IRF-3

IRF-3

p300/CBP

IFNβ

IP-10

RANTES

S100A8

S100A9

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
requires binding of all enhanceosome components, however, transcription can be stimulated from the IFN-β promoter following viral infection, through IRF-3 binding alone (121-123). Finally, activated IRF-3 is rapidly degraded through a proteasome-mediated pathway, ensuring that the inflammatory response will rapidly subside once the stimulus is eliminated (96, 105, 124).

i. b.) N-terminal phosphorylation

Phosphorylation in the N-terminal region of IRF-3 has been associated with cellular stimulation by stress inducers and DNA damaging agents, and is accomplished by DNA-protein kinase (DNA-PK) at Thr$^{135}$ and a member of the MAPK family at Ser$^{188}$ (101, 125-127). The functional implication of N-terminal phosphorylation has yet to be elucidated, although several different scenarios have been suggested. N-terminal phosphorylation via the stress-induced pathway may allow for a conformational change in IRF-3 structure, making the C-terminal Ser-Thr residues more accessible for phosphorylation by the VAK (101, 126). N-terminal phosphorylation may also serve to control IRF-3 activity prior to nuclear translocation (101, 109), and could also regulate the stability of the protein (96). Finally, it is possible that N-terminal phosphorylation has no effect on IRF-3 activity as a transcription factor, but could be involved in another distinct function of IRF-3. This latter hypothesis is based on an observation made by Servant et al. (101), that IRF-3 interacts with regulatory proteins that are not associated with transcriptional control.

ii. Virally-induced IRF-3 activation

IRF-3 is activated by many RNA viruses including SeV, MeV, NDV, VSV, and RSV, through VAK activation resulting from the detection of viral dsRNA produced within
the cell (99-102). Cellular receptors for dsRNA within the cell include PAMP receptors such as TLR-3, and cytoplasmic pattern recognition receptors such as RIG-I (retinoic acid inducible gene-I), a highly inducible RNA helicase that binds dsRNA (128, 129). Although the role of RIG-I and TLR-3 in dsRNA recognition are cell-type dependent, both are key activators of the IRF-3 activation pathway (130, 131). IRF-3 is also activated upon infection by the DNA viruses human CMV and HSV type I, and occurs in the absence of virally produced dsRNA. Virus internalization is required for HSV-mediated activation of IRF-3, whereas in CMV infection, binding to the cell is sufficient (103, 104).

iii. IFNs and viral resistance

Following early IRF-3-mediated induction of the type I IFN promoter, the resulting IFNα/β protein is secreted from the cell. Acting in an autocrine and paracrine fashion, these IFNs proceed to bind to and stimulate their common receptor on both the infected and neighboring cells (59). The stimulated receptor then activates a JAK/STAT (janus activated kinase/signal transducer and activator of transcription) signaling pathway, resulting in the expression of hundreds of IFN-stimulated genes (ISGs) which act to set up an antiviral, antiproliferative, and immunoregulatory state in host cells (53, 59, 132-139). The best-characterized ISGs are cellular antiviral proteins that act directly to prevent viral replication. These ISGs are induced in non-immune cells and include dsRNA-activated serine/threonine kinase protein kinase (PKR), enzymes 2',5'-oligoadenylate synthetase (OAS) and RNase L, and the myxovirus-resistance (Mx) proteins (53, 140).

Another ISG, IRF-7, is the closest relative of IRF-3 and shares common features (141). During the second phase of induction, heterodimeric IRF-3 and 7 bind PRD elements
to further enhance the expression of IFNα/β (142, 143). Indeed, the synthesis and activation of IRF-7 is required to bring about the induction of the rest of the IFN-α genes (39-40), as IRF-3 alone can only induce the expression of IFN-α4 (144). IRF-7, however, is also very distinct from IRF-3. Unlike IRF-3, inactive IRF-7 expression occurs mainly in lymphoid tissues at very low basal levels and is strongly induced by IFN treatment (141, 145). This represents a highly regulated system, since in the absence of continual IFN stimulus, IRF-7 levels drop significantly and the antiviral state within the cell is quickly reversed.

In addition to their role in ISG induction in non-immune cells, IFNs released from infected cells act as a signal for the recruitment and activation of immune cells such as macrophages, NK cells, and cytotoxic T lymphocytes (CTL) to the site of infection. Once they have relocated to the area, NK cells and CTL release a number of antiviral cytokines including TNF-α and IFN-γ (62, 146). These immunoregulatory cytokines act to control viral infections directly by purging the cell through cytopathic or non-cytopathic means, or indirectly, by modulating the induction, amplification, recruitment, and effector functions of the immune response (62).

Interestingly, IRF-3a functions in a dominant-negative manner and selectively impedes IFN-β production in response to viral infection. In this way, relative levels of IRF-3a in a cell can dictate the extent of IFN-β produced by that cell. *In vitro* experiments, however, have demonstrated that several-fold over-expression of IRF-3a in relation to IRF-3 is required for significant modulation of IRF-3 transcriptional activity (106).
iv. RANTES expression

The pro-inflammatory CC-chemokine RANTES is a well-established chemoattractant for leukocytes (eosinophils, basophils, monocytes), NK cells, and T cells, including memory T lymphocytes, during inflammation and the immune response (147-150). In addition, RANTES is also believed to be an important mediator of T-lymphocyte-dependent immune responses (75). Both RANTES and its receptor CCR (CC chemokine receptor)-5 have been associated with Th1 immune responses and play an important role in T cell activation (75, 151-154).

In many cell types including monocytes/macrophages, fibroblasts, and epithelial cells, RANTES is expressed within hours of pro-inflammatory stimulation (155). However, RANTES gene expression typically varies between tissue type and applied stimulus, since the transcriptional machinery controlling RANTES expression differs between the cell types (148, 155-159). As there exists a large number of potential consensus sites within the immediate upstream region of the RANTES promoter, multiple control points of expression must be present (160). Indeed, different combinations of cis-regulatory elements of the promoter are required for optimal levels of transcription in several types of immune cells following cytokine stimulation (148, 155-159). For example, in T lymphocytes, NF-κB, NF-IL-6 (nuclear factor of interleukin-6), NF-AT (nuclear factor of activated T cells), and CD28RE (CD28 response element) binding sites are important regulatory elements of RANTES promoter activity (148, 160). Late RANTES mRNA expression, which occurs 3-5 days after T-cell activation (161), is believed to occur through binding of the late transcription factor RFLAT-1 (RANTES factor of activated T-lymphocytes-1) to the RANTES promoter. RFLAT-1 is induced 3 days after T-cell activation, and is a strong activator of the RANTES promoter in T-cells (162).
Working synergistically with NF-κB, IRF-3 plays an essential role in virus-inducible activation of RANTES gene expression through its activation and binding to the ISRE (IFN stimulated response element) on the RANTES promoter (100, 148, 149, 163). In this way, RANTES expression can be directly induced by activated IRF-3 in the absence of cytokines such as TNF-α, IL-1, and IFN-γ that are produced during acute inflammation (143, 163-165). Therefore, if the virus is able to attenuate IFN function, the production of RANTES from the infected cell will still allow for the recruitment of immune cells to the site of infection.

Both in vivo and in vitro studies have demonstrated an induction of RANTES expression very soon after Ad vector transduction. For example, Otake et al. (66) observed the induction of RANTES in murine lung tissue within hours of Ad vector transduction, and Muruve et al. (34) observed the induction RANTES mRNAs in murine liver tissue within 60 minutes of Ad vector delivery. In studies with PBMC, Higginbotham et al. (72) observed a significant up-regulation of RANTES expression over a 96-hour window following in vitro infection with wtAd5, ΔE1 and/or ΔE3 Ad5 vectors, and empty Ad capsids. Early induction of RANTES has also been observed following Ad vector transduction in HeLa cells, and in mouse insulinoma cell line TGP61 (34, 75). Furthermore, in primary kidney epithelial cells, RANTES expression is induced within 6 hr of Ad vector transduction (38), and in other epithelium-derived cell lines, RANTES induction can occur within hours of Ad vector transduction, and in the absence of TNF-α or type I IFNs (34, 73-76). Thus, in many cell types, RANTES induction can be used as a measure of innate immune activation by Ad.
1.2 Objective

The inflammatory response that accompanies Ad infection can be problematic for gene therapy studies, or beneficial as in wild type Ad infection. In either case, this response occurs early, as it is stimulated by the binding and/or entry of the Ad capsid to the cell and does not require viral gene expression. To date, the signal transduction pathways that direct this inflammatory response to Ad are not completely understood. Several studies have described the important role of transcription factor NF-κB in the activation of pro-inflammatory cytokines and chemokines early in Ad infection. For many other viruses, another key transcription factor, IRF-3, also acts early in viral infection. In addition to its ability to initiate the recruitment of pro-inflammatory cytokines and chemokines, IRF-3 is also responsible for the activation of a number of genes involved in the antiviral interferon response. While most studies have examined the IRF-3 signal transduction pathway in response to RNA viruses, to date, little work has focused on the activation of this pathway and its role in response to infection by DNA viruses such as Ad, which have strikingly different genetics, kinetics, and life cycles than those of RNA viruses. Thus far, no studies have determined if Ad infection initiates the pathways responsible for the phosphorylation and activation of IRF-3. Consequently, in this project, we sought to determine if Ad infection activates IRF-3 and is important in establishing an antiviral state in Ad infected cells by acting as a transcription factor to up-regulate pro-inflammatory genes associated with the interferon response.

1.3 Hypothesis

Since a number of studies using RNA viruses have revealed an important role for IRF-3 in the antiviral interferon response that corresponds with early inflammation, we
believe that IRF-3 also plays an important role in response to infection by DNA viruses, specifically adenovirus. We hypothesize that IRF-3 is phosphorylated and activated following wtAd5 infection. Furthermore, we hypothesize that IRF-3 plays an important role in the establishment of antiviral resistance to wtAd5 infection, specifically as a transcription factor in the up-regulation of pro-inflammatory chemokine RANTES.

1.4 Approach

Phosphorylation status of IRF-3 will be analyzed in infected cells, and an attempt will be made to determine which amino acid residue(s) are phosphorylated in response to Ad infection. In addition, we will determine the importance of IRF-3 in the induction of RANTES in Ad-infected cells through the use of reporter constructs containing various regions and transcription factor binding sites from the RANTES promoter. Taken together, these data will elucidate the importance of IRF-3 in the induction of innate immunity in Ad-infected cells.

1.5 Rationale

To date, the innate immune response to Ad is not completely understood. The recent reemergence of Ad-induced ARD in confined populations, as well as the prevalence of other Ad-related diseases in children, the elderly, and immuno-compromised individuals, demonstrate the need for an Ad vaccine and an effective antiviral compound or form of immunotherapy against Ad. Conversely, a current emphasis in Ad gene therapy research is to determine the mechanisms by which Ad induces the early inflammatory response, and to modify Ad vectors accordingly in order to eliminate this very dangerous and even lethal problem.
In order to elucidate novel methods to combat severe Ad diseases and develop nontoxic Ad vectors for gene therapy, a greater understanding of the immune response to Ad is necessary. With the goal of identifying potential targets for intervention to enhance/repress the immune response to Ad, this project focuses specifically on the role of IRF-3, an important transcription factor that has not yet been investigated in Ad-induced immunity. *In vitro* characterization of the innate immune response to wtAd5 and Ad5-based vectors, with respect to IRF-3 activation, will map a major signaling pathway used by many viruses to combat infection, thus bringing new insight into the early immune response to Ad.
Chapter 2: MATERIALS AND METHODS

Reagents:
See Appendix A for list of reagents, solutions, and buffers used.

Cell culture and viral infections:

HeLa (human epithelium-derived; American Type Culture Collection [ATCC] CCL 2) and MRC5 (normal human lung fibroblast; ATCC CCL 171) cells were maintained in Dulbecco Modified Eagle Medium (DMEM, Sigma) supplemented with 10% fetal bovine serum (FBS), 1% GlutaMax, and 1% Antibiotic/Antimyotic (Invitrogen) at 37°C in 5% CO₂ atmosphere. 293 (166) and A549 (human lung epithelial adenocarcinoma; ATCC CCL 185) cells were maintained under the same conditions in Modified Eagle Medium (MEM, Sigma) supplemented with 10% FBS, 1% GlutaMax, and 1% Antibiotic/Antimycotic.

Wild type adenovirus serotype 5 was obtained from J. Bell (Ottawa Health Research Institute, Ottawa ON). Ad5 vectors used in the experiments were: AdCA35 (ΔE1Ad) from Addison et al. 1997 (167), AdRP2233 (E1⁺ΔE3Ad) from Sargent et al. 2004 (168), Δ28lacZ (hdAd) from Palmer and Ng 2003 (169), and Ad5ts36 (DNA polymerase, temperature sensitive mutant of Ad5) from Wilkie et al. 1973 (170). All Ad infections were performed in DMEM-PBS (DMEM-phosphate buffered saline, Sigma) at multiplicities of infection (MOI) ranging from 1 to 500 PFU/cell for 1 hour at 37°C. A Vesicular Stomatitis Virus expressing green fluorescent protein (VSV-GFP), provided by J. Bell (Ottawa Health Research Institute) was used as a positive control in all experiments. Infections with VSV were carried out in serum-free MEM at MOI ranging from 1 to 10 PFU/cell for 1 hour at 37°C.
IRF-3 plasmid constructs and mutagenesis:

For a complete list of mutant FLAG-tagged IRF-3 plasmids used, including a detailed description of their construction, see Appendix B. Briefly, FLAG-tagged human IRF-3 was cloned into pcDNA3. Various serine/threonine residues representing possible IRF-3 phosphorylation sites were then mutated to alanine in a series of cloning steps involving the insertion of various mutated oligonucleotides (Sigma) into the pcDNA-FLAG-IRF-3 vector. In order to simplify cloning steps, many of the IRF-3 mutant sequences were also cloned into pBluescriptKS+ (Stratagene) vectors. Plasmid DNA was transformed into RbCl competent cells (prepared as in (171)) by heat shock method. Small scale preparation of DNA was performed by alkaline lysis following methods described by Birnboim and Dolly (172), while large scale preparation of DNA was performed by alkaline lysis with purification by CsCl buoyant density centrifugation as described in Sambrook et al. (173). All constructs were sequenced by StemCore Labs (Ottawa Health Research Institute, Ottawa, ON) to confirm their identity.

RANTES promoter constructs and mutagenesis:

The RANTES promoter reporter constructs (-296, -181, -90, -296mutNF-κB) used in this project were provided by D.A. Muruve (University of Calgary, Calgary AB). For a summary of each construct, see Appendix B. An additional plasmid -181mutISRE, was constructed for these studies and contains point mutations within the IRES of the RANTES promoter (see Appendix B for details). Briefly, a fragment of pGL2-RANTES(-181) containing the IRES was cloned into a pBluescriptKS+ vector, oligonucleotides (Invitrogen) containing the IRES point mutations were cloned into the -181 fragment, and the mutated
-181 fragment was then cloned back into the pGL2-RANTES(-181) vector. The ISRE mutation was created in the -181 construct and not the -296 construct simply due to the ease at which the smaller fragment could be cloned in and out of the pBluescriptKS+ vector. Transformation of plasmid DNA and preparation of small/large scale DNA were performed as above. Mutations created in the -181mutISRE construct were confirmed by sequencing.

Transient transfections:

On the day prior to DNA transfection, 293 and HeLa cells were seeded at ~1.0x10^6 cells/35mm dish. Transfection of these cell lines were performed in serum-free MEM and DMEM with Lipofectamine 2000 (Invitrogen) as per manufacturer’s instructions. In all experiments, infection of transfected cells occurred 24 hr after transfection.

Immunoblot analysis:

HeLa, A549, MRC5, or 293 cells in 35mm dishes were harvested with 250 µL of 2x denaturing sample buffer containing β-mercaptoethanol, 10-15 µL of these lysates were subjected to electrophoresis on small or large format 7.5% acrylamide gels. Proteins were electrophoretically transferred onto PVDF membranes using semi-dry transfer (BioRad). The membranes were blocked in Tris-buffered saline (TBS) containing 5% nonfat dry milk and 0.1% Tween 20 (TBS-T), for 1 hr at room temperature with shaking, or at 4°C overnight. Primary and secondary antibodies were diluted in the blocking solution and incubated with the membranes at room temperature for 1 hr with shaking. After incubation with each antibody, the membranes were washed (with shaking) twice with TBS-T for 15 min at room temperature. The primary antibodies used in these studies were anti-IRF-3 rabbit polyclonal
(FL-425, Santa Cruz) (1:1700), anti-FLAG M2 mouse monoclonal (F3165-1MG, Sigma) (1:15000), anti-α-tubulin mouse monoclonal (Ab-1, Oncogene) (1:5000), and anti-p38 rabbit polyclonal (sc-535, Santa Cruz) (1:200). Secondary antibodies used in these studies were IgG (H+L)-HRP-conjugated goat anti-rabbit (BioRad) (1:5000) and goat anti-mouse (BioRad) (1:5000). Membranes were developed with Pierce ECL Western Blotting Substrate (Pierce) or using the ECL+ plus Western Blotting Detection System (Amersham BioSciences) according to the manufacturer's instructions. To remove bound antibody from membranes for re-probing, membranes were washed (with shaking) twice with TBS-T for 5 min at room temperature and incubated in 15-20 mL Restore Western Blot Stripping Buffer (Pierce) for 20 min at 37°C. Membranes were washed (with shaking) twice with TBS-T for 5 min at room temperature then blocked in blocking solution for 1 hr at room temperature with shaking, or 4°C overnight.

**Phosphatase treatment:**

After removal of culture medium, infected/mock-infected HeLa cells were washed twice with cold DMEM PBS. Cells were incubated in 30 μL RIPA (RadioImmunoPrecipitation Assay) buffer for 20 min, monolayers removed by scraping into an microcentrifuge tube, and cell debris removed by centrifugation for 15 min at 14000 x g, 4°C. The supernatent was divided into 4 separate tubes (70 μL each), and 10 mM MgCl₂ (final concentration) was added to each. Phosphatase treatment was started by adding calf intestinal phosphatase (CIP, New England Biolabs) to 3 of the 4 tubes in increasing concentrations (50, 200, 500 units). The first tube was not treated with CIP, but with the following phosphatase inhibitors: (final concentration) 10 mM NaF, 0.4 mM Na₃VO₄. The
reactions were incubated overnight at 37°C, after which 2x denaturing sample buffer was added to each tube. The samples were then resolved by SDS-PAGE, and analyzed by immunoblotting using anti-IRF-3 antibody.

*Luciferase Assays:*

After removal of culture medium, HeLa cells were harvested with 300 µL (for a 35mm dish) of Reporter Lysis Buffer (Promega) and frozen at -80°C. Cell lysates were thawed and pelleted after centrifugation at 14000 x g at 4°C for 2 min. Cell supernatant (50 µL) was added to 100 µL of Luciferase Assay Substrate (Promega), and luciferase activity was measured in relative luciferase units using a Lumat LB 9507 luminometer (EG&G Berthold).
Chapter 3: RESULTS

IRF-3 is phosphorylated rapidly after VSV infection and late after wtAd5 infection

Through immunoblot analysis, many studies have demonstrated IRF-3 phosphorylation in response to infection by RNA viruses (MeV, SeV, NDV, RSV, VSV) (99-101). This phosphorylation can be visualized as a shifting of band intensity from non-phosphorylated IRF-3 isoform I to a more slowly migrating isoform (form II) and by the presence of phosphorylated forms III and IV (indicative of IRF-3 activation), all of which are about 55kDa and can be detected by SDS-PAGE (96, 101, 108). For simplicity, a change in phosphorylation from that observed in mock-infected cells to a more highly phosphorylated form (i.e. a greater proportion of total IRF-3 located within the more highly phosphorylated isoform) will henceforth be referred to simply as “phosphorylation of IRF-3”.

In order to examine IRF-3 phosphorylation in response to VSV infection, A549 cells were mock-infected or infected with VSV (MOI 10 PFU/cell) and harvested at 2, 6, and 24 hr post-infection for SDS-PAGE and immunoblot analysis. At 2 hr post-infection, there was no evidence of IRF-3 phosphorylation. However, by 6 hr, IRF-3 phosphorylation was confirmed through the detection of IRF-3 phosphorylated form III (Fig. 6A). Finally at 24 hr post-infection, IRF-3 was only detectable as isoform II, thus indicating degradation of activated IRF-3. A similar experiment using HeLa cells also demonstrated phosphorylation of IRF-3 at 6 hr following VSV infection, however the presence of IRF-3 phosphorylated form III could not be detected in this cell line (data not shown). Taken together, this data supports previous studies that IRF-3 is phosphorylated and activated after VSV infection, and also shows that this event coincides with VSV genome replication.
Figure 6. VSV and wtAd5-induced IRF-3 phosphorylation.
(A) A549 cells were mock-infected or infected with VSV (MOI 10 PFU/cell). (B) A549 cells were mock-infected (-) or infected with wtAd5 (MOI 1, 10, 50, 100, and 500 PFU/cell). In panels A and B, cell lysates were harvested with 2x denaturing sample buffer at 2, 6, and 24 hr post-infection, resolved by large format 7.5% SDS-PAGE, transferred to a PVDF membrane, and probed using anti-IRF-3 antibody (Santa Cruz). IRF-3 phosphorylation forms I, II, and III are indicated on each panel. Blots were re-probed with an antibody against α-tubulin to ensure equal loading.
Although IRF-3 phosphorylation has been widely demonstrated to occur in response to infection by RNA viruses (99-101), phosphorylation of IRF-3 following Ad infection has not yet been investigated. To determine if wtAd5 infection leads to IRF-3 phosphorylation, A549 cells were mock-infected or infected with wtAd5 at increasing MOI (1-500 PFU/cell), and harvested at 2, 6, and 24 hr post-infection for SDS-PAGE and immunoblot analysis. At 2 hr post-infection, regardless of the MOI used on the cells, there was no evidence that IRF-3 phosphorylation had occurred (Fig. 6B). However, at 6 hr post-infection in cells infected at an MOI of 500 PFU/cell only, IRF-3 phosphorylation was evidenced as a shift in band intensity from non-phosphorylated IRF-3 isoform I to isoform II. At 24 hr after infection, this shift in band intensity was detected in all samples. Furthermore, as the MOI increased, so did the proportion of IRF-3 isoform II, so that at MOIs of 50, 100, and 500 PFU/cell, almost all IRF-3 was present in the upper isoform II band. Regardless of the MOI used, the presence of IRF-3 phosphorylated form III was not detected at 2, 6, or 24 hr post-infection. Comparable experiments with wtAd5-infected HeLa and MRC5 (normal human lung fibroblast) cells demonstrated a similar pattern of late IRF-3 phosphorylation (24 hr) without the detection of IRF-3 phosphorylated form III (data not shown). Although the band pattern in the tubulin loading control is uniform, in some instances it appears as though there may be more total IRF-3 when comparing IRF-3 isoform bands between sample lanes. It should be noted that while further testing is warranted, recent experiments in the Parks Lab have demonstrated that IRF-3 may be transcriptionally upregulated upon wtAd5 infection (~2 to 3-fold, R. Parks, personal communication).

To establish that the shift in IRF-3 band intensity observed in response to wtAd5 infection was due to phosphorylation, lysates of mock and wtAd5 infected HeLa cells were subjected to overnight treatment with increasing concentrations of calf intestinal phosphatase.
(CIP) before separation by SDS-PAGE and subsequent immunoblot analysis. Although the presence of the upper IRF-3 band corresponding to phosphorylation form II remained detectable, the intensity of the band was dramatically diminished after CIP treatment, suggesting sensitivity to phosphatase treatment (Fig. 7). Therefore, the shift in IRF-3 band intensity observed in wtAd5-infected cells can be attributed to increased phosphorylation. Taken together, this data indicates that although IRF-3 phosphorylation form III is not detected, wtAd5 does induce phosphorylation of IRF-3. Furthermore, this phosphorylation event occurs late (24 hr) regardless of MOI, yet can occur early (6 hr) when cells are infected at a high MOI.

WtAd5 immunomodulatory genes affect IRF-3 phosphorylation

Much of the Ad E3 gene region codes for viral immunoregulatory genes that target processes essential for the survival of the virus during acute and latent infection (5). To investigate if these immunomodulatory genes affect wtAd5-induced IRF-3 phosphorylation, A549 cells were mock-infected or infected with an E1ΔE3Ad at increasing MOI (1-500 PFU/cell), and harvested at 24 hr post-infection for SDS-PAGE and immunoblot analysis. As previously described, at 24 hr post-infection, IRF-3 phosphorylation in wtAd5-infected A549 cells increased with increasing MOI, such that at MOIs of 50, 100, and 500 PFU/cell, almost all IRF-3 was present in the upper isoform II band (Fig. 6B). However, at 24 hr after E1ΔE3Ad infection, from MOIs of 10 PFU/cell onward, almost all IRF-3 was present in the upper isoform II band (Fig. 8). Additionally, at an MOI of 1 PFU/cell, the proportion of IRF-3 present in the lower isoform I band was comparable to that of wtAd5-infected cells at an MOI of 10 PFU/cell (Fig. 6B). From this data, it appears as though the proteins
Figure 7. Phosphatase sensitivity of wtAd5-induced IRF-3 phosphorylation.
HeLa cells were mock-infected (-) or infected with wtAd5 (MOI 10 PFU/cell). At 24 hr post-infection, cell lysates were harvested with RIPA buffer containing protease inhibitors. Lysates were subjected to overnight treatment with increasing concentrations of calf intestinal phosphatase (CIP), or phosphatase inhibitors (PI: NaF, Na$_3$VO$_4$) only (lanes 1 and 5) at 36°C. An equal volume of 2x denaturing sample buffer was added and the lysates were separated by 7.5% SDS-PAGE, transferred to a PVDF membrane and probed using anti-IRF-3 antibody (Santa Cruz).
<table>
<thead>
<tr>
<th></th>
<th>(-)</th>
<th></th>
<th>wtAd5</th>
</tr>
</thead>
<tbody>
<tr>
<td>CIP</td>
<td>-</td>
<td>5</td>
<td>20</td>
</tr>
<tr>
<td>PI</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

IRF-3
Figure 8. IRF-3 phosphorylation in ΔE3Ad infection at increasing MOI.
A549 cells were mock-infected or infected with E1⁺ΔE3Ad (AdRP2233, MOI 1, 10, 50, 100, and 500 PFU/cell). Cell lysates were harvested with 2x denaturing sample buffer at 24 hr post-infection, resolved by large format 7.5% SDS-PAGE, transferred to a PVDF membrane, and probed using anti-IRF-3 antibody (Santa Cruz). IRF-3 phosphorylation forms I and II are indicated on each panel. The blot was re-probed with an antibody against α-tubulin to ensure equal loading (data not shown).
IRF-3

Form II
Form I

$E3^{(-)}$Ad (MOI)

1 10 50 100 500

24hr

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
encoded within the E3 region may act to reduce phosphorylation of IRF-3 in the infected cell.

WtAd5-induced IRF-3 phosphorylation is replication-dependent

Interestingly, late wtAd5-induced IRF-3 phosphorylation occurs during the same time frame as the peak of Ad DNA replication. Two experiments were conducted to investigate whether virus replication is important for IRF-3 phosphorylation to occur in wtAd5-infected cells. First, HeLa cells were mock-infected or infected with wtAd5 (MOI 10 PFU/cell) or Ad5ts36 (MOI 10 PFU/cell), a temperature sensitive virus able to replicate at 32.5°C but not 38.5°C (170). The infected cells were incubated at 32.5°C or 38.5°C, and assayed for IRF-3 phosphorylation 24 and 48 hr after infection. Using immunoblot analysis, IRF-3 phosphorylation was detected at either temperature in the wtAd5-infected cells, however, for cells infected with Ad5ts36, phosphorylation of IRF-3 occurred only at the permissive temperature, 32.5°C, suggesting a requirement for DNA replication (Fig. 9). Basal differences in the proportion of IRF-3 phosphorylation forms I and II at 24 hrs in cells infected with wtAd5 incubated at different temperatures is most likely the result of Ad replication occurring more rapidly at the higher temperature.

In the next experiment, HeLa cells were mock-infected or infected with an E1-deleted Ad (ΔE1Ad) at increasing MOI (10-500 PFU/cell) or a hdAd (MOI 500 PFU/cell). At 24 hr post-infection, cells were harvested for separation by SDS-PAGE and subsequent immunoblot analysis. Although ΔE1Ads are replication deficient vectors, at very high MOI ΔE1Ads can circumvent the replication block created by the deletion of the E1 gene region (174). Regardless of MOI, hdAds are incapable of replication and, as such, IRF-3

42

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 9. IRF-3 phosphorylation in temperature sensitive Ad5ts36 infection. HeLa cells were mock-infected (-) or infected with wtAd5 (MOI 10 PFU/cell) or Ad5ts36 (MOI 10 PFU/cell) and incubated at 32.5°C or 38.5°C. Cell lysates were harvested with 2x denaturing sample buffer at 24 and 48 hr post-infection, resolved by large format 7.5% SDS-PAGE, transferred to a PVDF membrane, and probed using anti-IRF-3 antibody (Santa Cruz).
IRF-3

(-) wtAd5 Ad5ts36 wtAd5 Ad5ts36

24hr 48hr 24hr 48hr 24hr 48hr 24hr 48hr

38.5°C 32.5°C 38.5°C

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
phosphorylation was not detected in the hdAd-infected cells (Fig. 10). In contrast, in the ΔE1Ad-infected cells, slight increases in the proportion of IRF-3 localized to isoform II were observed with increasing MOI, but IRF-3 phosphorylation was most apparent at an MOI of 500 PFU/cell, an MOI at which ΔE1Ad can replicate in HeLa cells. Data obtained from these two experiments clearly demonstrate that wtAd5-induced IRF-3 phosphorylation does not occur in the absence of replication. Thus, wtAd5-induced IRF-3 phosphorylation is replication-dependent.

The primary target for wtAd5-induced IRF-3 phosphorylation is a novel residue(s)

Phosphorylation of the IRF-3 protein can occur in four different regions: two within the N-terminus (residues Thr^{135} and Ser^{188}), and two within the C-terminus (residues Ser^{385}/Ser^{386}, and Ser^{396}/Ser^{398}/Thr^{402}/Ser^{405}) (96). The functional implication of N-terminal phosphorylation has yet to be fully elucidated, although, it is known that DNA-PK phosphorylation of Thr^{135} leads to nuclear retention of IRF-3, and that Ser^{188} is phosphorylated by a member of the MAPK family in response to stress and DNA damage (96, 101). Alternatively, C-terminal phosphorylation is indicative of IRF-3 activation, and occurs upon viral infection (96, 101, 105, 109, 110). The exact phosphorylation site required for virus-induced IRF-3 activation is still unclear, however experiments by Mori et al. and Servant et al. using SeV have narrowed down the most probable residues to Ser^{386} (108) or Ser^{396} (99).

To determine which amino acid residues of IRF-3 were phosphorylated in response to wtAd5 infection, a series of mutant FLAG-tagged IRF-3 plasmids containing substitutions of serine/threonine to alanine were generated for all known IRF-3 phosphorylation sites. These
Figure 10. IRF-3 phosphorylation in ΔE1Ad infection at increasing MOI.
HeLa cells were mock-infected (-) or infected with ΔE1Ad (AdCA35, MOI 10, 50, 100, and 500 PFU/cell) or hdAd (Δ28iacZ, MOI 500 PFU/cell). Cell lysates were harvested with 2x denaturing sample buffer at 24 hr post-infection, resolved by 7.5% SDS-PAGE, transferred to a PVDF membrane, and probed using anti-IRF-3 antibody (Santa Cruz). The blot was re-probed with an antibody against α-tubulin to ensure equal loading (data not shown).
IRF-3

E1(Ad5) 10 50 100 500 500

hdAd
included mutations at Ser\(^{385}/\)Ser\(^{386}\) (mut2A) and Ser\(^{396}/\)Ser\(^{398}/\)Thr\(^{404}/\)Ser\(^{405}\) (mut5A) within the C-terminus, as well as residues Thr\(^{135}\) (mut135) and Ser\(^{188}\) (mut188) within the N-terminus (Fig. 11A). A FLAG-tagged wild-type IRF-3 plasmid (wtIRF-3) was also created. All constructs were sequenced to confirm their identity. Equal expression of the constructs was confirmed by transfection into 293 cells, which were harvested for immunoblot analysis after 24 hr (Fig. 11B). The mutant FLAG-tagged IRF-3 plasmids were then transfected into HeLa cells, and either mock-infected or infected with wtAd5 (MOI 10 PFU/cell) 24 hr later. Cell lysates were harvested 24 hr post-infection for immunoblot analysis. Following wtAd5-infection, there was no significant effect on IRF-3 band distribution (Fig. 12), as most of the mutant proteins exhibited a similar distribution. Curiously, form II was detected with over-expression of the all-mutant IRF-3 construct (mut135/188/2A/5A). Since this construct is mutated in all known phosphorylation sites, this suggests there is another, as yet unidentified phosphorylation site that is normally partially phosphorylated in HeLa cells and is specifically hyperphosphorylated upon Ad infection.

**RANTES induced after wtAd5 infection occurs late and is replication-dependent**

The data shown above clearly demonstrates that Ad infection induces the phosphorylation of IRF-3. In the Ad-infected cell, phosphorylation appears to occur on a residue not previously identified in the literature. Importantly, mutation of amino acids previously associated with IRF-3 activation by RNA viruses (Ser\(^{386}\) and Ser\(^{396}\)) did not significantly alter the pattern of IRF-3 phosphorylation, as determined by immunoblot analysis. However, Collins *et al.* (175) have suggested that only a minor proportion of IRF-3 needs to be activated in a cell in order for a full interferon response to occur, and that this may not be detectable as a visible change in IRF-3 phosphorylation status by SDS-PAGE.
Figure 11. Mutant IRF-3 plasmids used to determine phosphorylation site(s) in wtAd5 infection. (A) Schematic representation of human IRF-3. The region between residues 128-142, 186-198, and 382-414 are expanded below the schematic to demonstrate the amino acids, in large letters, targeted for alanine substitutions. The point mutations are indicated below the sequence: T135A, S188A, 2A (S385A, S386A), and 5A (S396A, S398A, S402A, T404A, S405A). (B) Mutant FLAG-tagged IRF-3 plasmids mut135/188/2A/5A, mut2A/5A, mut135/188, mut2A, mut5A, mut135, and mut188 as well as a wt FLAG-tagged IRF-3 plasmid, were transfected into 293 cells to verify expression. At 24 hr post-transfection, cell lysates were harvested with 2x denaturing sample buffer, resolved by 7.5% SDS-PAGE, transferred to a PVDF membrane, and probed using anti-FLAG M2 antibody (Sigma). Panel A is an adaptation of a figure from Servant et al. 2002 (96).
Figure 12. Analysis of wtAd5-induced IRF-3 phosphorylation.
HeLa cells were transfected with the FLAG-tagged IRF-3 plasmids, mut135/188/2A/5A, mut2A/5A, mut135/188, mut2A, mut5A, mut135, and mut188, and wt IRF-3. At 24 hr post-transfection, cells were mock-infected (-) or infected with wtAd5 (MOI 10 PFU/cell). Cell lysates were harvested with 2x denaturing sample buffer at 24 hr post-infection, resolved by large format 7.5% SDS-PAGE, transferred to a PVDF membrane, and probed using anti-FLAG M2 antibody (Sigma). The blot was re-probed with an antibody against p38 to ensure equal loading (data not shown).
Therefore, an examination of IRF-3 activation was conducted by investigating its role in establishing an anti-viral state in wtAd5-infected cells. This was carried out by specifically examining the importance of IRF-3 as a transcription factor in the upregulation of the pro-inflammatory chemokine RANTES. Working synergistically with NF-κB, IRF-3 is known to play an essential role in virus-induced activation of RANTES gene expression through binding to the ISRE on the RANTES promoter (100, 148, 149, 163).

In this experiment, HeLa cells were transfected with the luciferase reporter construct pGL2-RANTES(-296) containing a fragment of the human RANTES promoter from position -296 (296 nucleotides from the transcription start site) (75). After 24 hr, transfected cells were either mock-infected or infected with wtAd5 (MOI 10 PFU/cell), and at 2 or 24 hr post-infection, crude lysates were prepared and assayed for luciferase activity. At 2 hr post-infection, luciferase activity levels were comparable in the mock and wtAd5-infected cells (Fig. 13). However, by 24 hr, there was a 7-fold increase in luciferase activity in the wtAd5-infected cells as compared to the mock-infected cells. This increase in luciferase activity represented a 3-fold increase in the induction of RANTES expression from 2 to 24 hr in wtAd5-infected cells. In a similar experiment, HeLa cells were transfected with pGL2-RANTES(-296), and 24 hr later were mock-infected or infected with wtAd5 at increasing MOI (1-100 PFU/cell). Cell lysates were harvested and assayed for luciferase activity 24 hr post-infection. Luciferase activity increased with increasing MOI to a maximum at an MOI of 50 PFU/cell (Fig. 14). At an MOI of 100 PFU/cell, luciferase activity levels were comparable to those measured in cells that were infected at an MOI of 10 PFU/cell; however, at an MOI of 100, the cell monolayer showed significant cytopathic effect, suggesting the virus had caused substantial cell death at the higher MOI. These data indicate that RANTES expression is induced by wtAd5, and this occurs late in the Ad life cycle.

49

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 13. WtAd5-induced RANTES expression.
HeLa cells were transfected with the luciferase reporter construct pGL2-RANTES(-296) containing a fragment of the human RANTES promoter (Bowen et al. (75)), and either mock-infected or infected with wtAd5 (MOI 10 PFU/cell) 24 hr post-transfection. Cell lysates were harvested with reporter lysis buffer at 2 or 24 hr post-infection and analyzed for luciferase activity (expressed in RLU, relative light units). Each value represents the average of duplicate samples, while error bars represent the range between duplicate samples. The data are representative of two different experiments with similar results. Statistical analysis was preformed by a two-tailed Student’s t-Test assuming two-sample equal variance. Statistically significant differences (p ≤ 0.025) are noted (**).
RANTES Promoter (-296) → Luciferase

Luciferase Activity (x10^3 RLU)

- Uninfected
- Infected with wtAd5

Time Post-Infection

2 24

0 5 10 15 20

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 14. Optimal MOI for wtAd5-induced RANTES expression.
HeLa cells were transfected with pGL2-RANTES(-296) and either mock-infected (-) or infected with wtAd5 (MOI 1, 10, 50, and 100 PFU/cell) 24 hr post-transfection. Cell lysates were harvested with reporter lysis buffer at 24 hr post-infection and analyzed for luciferase activity (expressed in RLU, relative light units). Each value represents the average of duplicate samples, while error bars represent the range between duplicate samples. The data are representative of three different experiments with similar results. Statistical analysis was performed by a two-tailed Student's t-Test assuming two-sample equal variance.
Curiously, like wtAd5-induced IRF-3 phosphorylation, this late wtAd5-induced RANTES expression occurs during the peak of Ad DNA replication. To determine if virus replication is important for RANTES expression in wtAd5-infected cells, HeLa cells were transfected with pGL2-RANTES(-296), and 24 hr later were mock-infected or infected with an ΔE1Ad at increasing MOI (1-100 PFU/cell). Luciferase activity was assayed from cell lysates that were harvested 24 hr post-infection. As previously mentioned, ΔE1Ads are replication deficient vectors, but can circumvent the replication block imposed by the deletion of the E1 gene region at very high MOI (174). In this assay, a notable increase in luciferase activity was not apparent until cells were infected with the ΔE1Ad at an MOI of 100 PFU/cell, an MOI at which ΔE1Ad can replicate in HeLa cells (Fig. 15). This increase in luciferase activity represented a 10-fold increase in the level of RANTES expression when compared to the level measured in the mock-infected cells. Together, these data suggest that like IRF-3 phosphorylation, RANTES expression following wtAd5 infection occurs late and is dependent on viral replication.

*Full induction of RANTES expression after wtAd5 infection is dependent on IRF-3*

Virus-inducible activation of RANTES gene expression is regulated through binding of both IRF-3 and NF-κB to specific binding domains on the RANTES promoter (100, 148, 149, 163). To determine the relative contribution of each transcription factor to RANTES expression, HeLa cells were transfected with a series of luciferase reporter constructs containing deletional mutants of the fragment of the human RANTES promoter contained within pGL2-RANTES(-296) (75). While constructs pGL2-RANTES(-296) and pGL2-RANTES(-181) contain both NF-κB and IRF-3 binding sites, pGL2-RANTES(-90) contains
Figure 15. ΔE1Ad-induced RANTES expression.
HeLa cells were transfected with pGL2-RANTES(-296) and either mock-infected (-) or infected with ΔE1Ad (AdCA35, MOI 10, 50, 100, and 500 PFU/cell) 24 hr post-transfection. Cells lysates were harvested with reporter lysis buffer at 24 hr post-infection and analyzed for luciferase activity (expressed in RLU, relative light units). Each value represents the average of duplicate samples, while error bars represent the range between duplicate samples. The data are representative of three different experiments with similar results. Statistical analysis was preformed by a two-tailed Student’s t-Test assuming two-sample equal variance.
RANTES
Promoter (-296) → Luciferase

Luciferase Activity (x10^4 RLU)

(-)  E1(C)Ad5 (MOI)

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
only the NF-κB binding sites, and pGL2-RANTES(-296mutκB) contains point mutations within the NF-κB binding sites thus containing only the IRF-3 binding sites (Fig. 16A). At 24 hr post-transfection, the HeLa cells were either mock-infected or infected with wtAd5 (MOI 50 PFU/cell), and luciferase activity was assayed from cell lysates that were harvested 24 hr post-infection. We observed significant increases in luciferase activity levels in each of the transfected wtAd5-infected cells when compared to their mock-infected counterparts (Fig. 16B). However, relative to the -296 construct, wtAd5-infected cells that were transfected with -90 and -296mutκB induced almost 2-fold and 8-fold less luciferase activity, respectively. Furthermore, wtAd5-infected cells that were transfected with -90 induced 5-fold more luciferase activity than -296mutκB-transfected cells. These data suggest while IRF-3 is important in wtAd5-induced RANTES expression, a slightly higher level of RANTES expression can be attributed to NF-κB binding activity. Nevertheless, both NF-κB and IRF-3 are required for full RANTES induction.

It is possible that decreased luciferase activity observed in the pGL2-RANTES(-90) wtAd5-infected cells, as compared to the -296 and -181 wtAd5-infected cells, could be influenced by structural and conformational restrictions placed on the -90 construct due to its significantly truncated RANTES promoter region. Therefore, we generated a luciferase reporter construct containing point mutations within the IRF-3 binding site of a longer RANTES promoter (-181mutISRE) (Fig. 17A). HeLa cells were transfected with pGL2-RANTES(-296), pGL2-RANTES(-181), pGL2-RANTES(-296mutκB), or pGL2-RANTES(-181mutISRE), and either mock-infected or infected with wtAd5 (MOI 10 PFU/cell) 24 hr post-transfection. Cell lysates were harvested and assayed for luciferase activity 24 hr post-infection. A significant increase in luciferase activity levels was observed in wtAd5-infected
Figure 16. Contribution of IRF-3 and NF-κB in wtAd5-induced RANTES expression as observed using fragments of a deletional mutant of the human RANTES promoter. (A) Schematic representation of the human RANTES promoter reporter constructs used in this study. All reporter constructs contain fragments of the RANTES promoter, however, -296 and -181 contain both NF-κB and IRF-3 binding sites, while -90 contains the NF-κB binding sites alone. The -296mutKB construct contains point mutations within the NF-κB binding sites. All constructs are from Bowen et al. 2002 (75). (B) HeLa cells were transfected with luciferase reporter constructs pGL2-RANTES(-296), pGL2-RANTES(-181), pGL2-RANTES(-296mutKB), or pGL2-RANTES(-90), and either mock-infected or infected with wtAd5 (MOI 50 PFU/cell) 24 hr post-transfection. Cells lysates were harvested with reporter lysis buffer at 24 hr post-infection and analyzed for luciferase activity (expressed in RLU, relative light units). Each value represents the average of duplicate samples, while error bars represent the range between duplicate samples. The data are representative of three different experiments with similar results. Statistical analysis was performed by a two-tailed Student’s t-Test assuming two-sample equal variance. Statistically significant differences (p \leq 0.025) are noted (**).
A

IRF-3 binding sites

-296
-181
-90
-296mutkB

IRF-3 binding sites

-296
-181
-90
-296mutkB

B

Luciferase Activity (x10^4 RLU)

Uninfected

Infected with wtAd5

-296
-181
-90
-296mutkB

**

**

**

**
Figure 17. Contribution of IRF-3 and NF-κB in wtAd5-induced RANTES expression as observed using human RANTES promoter constructs containing point mutations within IRF-3 and NF-κB binding sites. (A) Schematic representation of the human RANTES promoter reporter constructs containing point mutations. Sequences of wild-type and mutated RANTES promoters are expanded below the schematic and nucleotide substitutions introduced in the ISRE or NF-κB binding motifs are underlined. All constructs with the exception of -181mutISRE, which was constructed for this project, are from Bowen et al. 2002 (75). Panel A is based on a figure from Génin et al. 2000 (149). (B) HeLa cells were transfected with luciferase reporter constructs pGL2-RANTES(-296), pGL2-RANTES(-296mutKB), or pGL2-RANTES(-181mutISRE), and either mock-infected or infected with wtAd5 (MOI 10 PFU/cell) 24 hr post-transfection. Cells lysates were harvested with reporter lysis buffer at 24 hr post-infection and analyzed for luciferase activity (expressed in RLU, relative light units). Each value represents the average of duplicate samples, while error bars represent the range between duplicate samples. The data are representative of two different experiments with similar results. Statistical analysis was performed by a two-tailed Student’s t-Test assuming two-sample equal variance. Statistically significant differences (p ≤ 0.025) are noted (**).
A

![Diagram of binding sites and Luc reporter](image)

**ISRE**
- -296
- -181
- -90

**NF-kB**
- -296
- -181
- -90

Wild type RANTES
(-296, -181, -90)

RANTES Mutant (ISRE)
(-181mutISRE)

RANTES Mutant (kB)
(-296mutkB)

B

![Bar graph of luciferase activity](image)

- Uninfected
- Infected with wtAd5

Luciferase Activity (x10^3 RLU)

-296
-181
-181mutISRE
-296mutkB

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
cells that were transfected with -296 and -181 compared to their mock-infected counterparts (105 and 120-fold increases, respectively) (Fig. 17B). In comparison, while cells transfected with -181mutISRE and -296mutκB also demonstrated increased luciferase activity levels upon wtAd5-infection when compared to mock infected levels (75 and 56-fold, respectively), these increases were not as high as those observed in cells transfected with the unmutated -296 and -181 constructs. Similar to our previous experiment, these data suggest that binding to both the ISRE and the NF-κB binding site are required for optimal RANTES induction in wtAd5-infected cells. However, in this experiment, a more complete model of RANTES promoter activity, abrogation of NF-κB and IRF-3 binding caused comparable decreases in RANTES expression, suggesting that IRF-3 and NF-κB contribute equally to wtAd5-induced RANTES expression.

*Over-expression of phosphorylation-mutant IRF-3 reduces wtAd5-mediated RANTES induction*

To further examine whether IRF-3 is important for RANTES induction in wtAd5-infected cells, expression from a RANTES luciferase reporter construct was characterized in the presence of over-expressed wildtype or dominant-negative IRF-3. In the first experiment, HeLa cells were co-transfected with pGL2-RANTES(-296) and either wtIRF-3 or an empty pcDNA3 plasmid. After 24 hr, cells were mock-infected or infected with wtAd5 (MOI 10 PFU/cell), and cell lysates were harvested and assayed for luciferase activity 24 hr post-infection. Luciferase analysis demonstrated that transfection of wtIRF-3 resulted in a significant increase in luciferase expression (Fig.18C), suggesting that over-expression of wtIRF-3 in Ad-infected cells leads to increased levels of RANTES expression.
Figure 18. IRF-3 activation in wtAd5-induced RANTES expression.

(A) Schematic representation of the human RANTES luciferase reporter construct. (B) Schematic representation of an IRF-3 phosphorylation-mutant construct. The region between residues 382-414 is expanded below the schematic to demonstrate the amino acids, in large letters, in this construct that were targeted for alanine substitutions. The point mutations are indicated below the sequence: 2A (S385A, S386A) and 5A (S396A, S398A, S402A, T404A, S405A). (C) HeLa cells were co-transfected with pGL2-RANTES(-296) and either wtIRF-3 or empty pcDNA3, and mock-infected or infected with wtAd5 (MOI 10 PFU/cell) 24 hr post-transfection. (D) HeLa cells were co-transfected with pGL2-RANTES(-296) and either wtIRF-3 or IRF-3(mut2A/5A), and mock-infected or infected with wtAd5 (MOI 10 PFU/cell) 24 hr post-transfection. In panels C and D, cell lysates were harvested with reporter lysis buffer at 24 hr post-infection and analyzed for luciferase activity (expressed in RLU, relative light units). Each value represents the average of duplicate samples, while error bars represent the range between duplicate samples. Statistical analysis was preformed by a two-tailed Student's t-Test assuming two-sample equal variance. Statistically significant differences (p ≤ 0.025) are noted (**).
In the second experiment, HeLa cells were co-transfected with pGL2-RANTES(-296) and either wtIRF-3 or IRF-3(mut2A/5A). After 24 hr, cells were either mock-infected or infected with wtAd5 (MOI 10 PFU/cell), and cell lysates were harvested and assayed for luciferase activity 24 hr post-infection. Transfection of IRF-3(mut2A/5A) resulted in an over 2-fold decrease in luciferase expression, compared to cells transfected with the wtIRF-3 expression construct (Fig.18D). These data suggest that full induction of RANTES does not occur when IRF-3 phosphorylation at C-terminal residues Ser\textsuperscript{396}, Ser\textsuperscript{398}, Ser\textsuperscript{402}, Thr\textsuperscript{404} and Ser\textsuperscript{405}, in addition to residues Ser\textsuperscript{385} and Ser\textsuperscript{386}, is not permitted. Taken together, both experiments clearly suggest that IRF-3 phosphorylation at residues located within the 382-414 region of the IRF-3 C-terminus are important in wtAd5-induced activation of IRF-3, and therefore provide additional evidence that IRF-3 activation is important for RANTES expression in wtAd5 infection.

In summary these data suggest that wtAd5 infection results in phosphorylation of IRF-3 on a novel amino acid residue, and this event is dependent on virus replication. Moreover, IRF-3 is an important transcription factor for induction of RANTES expression in wtAd5-infected cells. Taken together, these data suggest that IRF-3 activation in response to Ad DNA replication is important in establishing an anti-viral state within the infected cell.
Chapter 4: DISCUSSION

Adenovirus infection, both naturally and after delivery of an Ad-based gene therapy vector, is accompanied by a strong inflammatory response initiated by the induction of the innate immune response. This response occurs very early, and is stimulated by the binding and/or entry of the Ad capsid to the cell and does not require viral gene expression. Although the signal transduction pathways that direct the innate immune response to Ad are not yet fully elucidated, much evidence has linked transcription factor NF-κB to the activation of pro-inflammatory cytokines and chemokines early in Ad infection. For many RNA viruses, another key transcription factor, IRF-3, is also known to act early in viral infection. Like NF-κB, IRF-3 can initiate pro-inflammatory cytokine and chemokine expression, and is also responsible for the activation of a number of genes involved in the antiviral interferon response. Although many studies have examined the IRF-3 signal transduction pathway in response to RNA viruses, few studies have examined the role of IRF-3 in activating immune responses to DNA viruses.

The goal of this research was to determine if IRF-3 plays a role in the induction of innate immunity against Ad. We hypothesized that following wtAd5 infection, IRF-3 is phosphorylated and activated in order to participate in the establishment of antiviral resistance to wtAd5 infection. Our data indicates that wtAd5 infection results in the phosphorylation of IRF-3 on a novel amino acid residue, and this phosphorylation event is dependent on viral replication. Moreover, in wtAd5-infected cells, IRF-3 is an important transcription factor for the induction of RANTES, our model inflammatory chemokine. Finally, our data also suggests that Ad-infection results in at least two phosphorylation events on IRF-3: one event occurring in the N-terminus (discussed below) resulting in a protein shift

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
observed by SDS-PAGE and a second event occurring in the C-terminus of a small portion of IRF-3 within the cell leading to activation. Taken together, these data indicate that IRF-3 activation in response to Ad DNA replication is important in establishing an antiviral state within the infected cell.

WtAd5-induced IRF-3 phosphorylation

To establish a positive control capable of serving as a model for the detection of wtAd5-induced IRF-3 phosphorylation, we first studied IRF-3 phosphorylation in response to VSV infection. VSV has been shown previously to activate IRF-3 (99, 101, 102). Through immunoblot analysis of lysates from VSV-infected A549 cells, we detected IRF-3 phosphorylation by the appearance of IRF-3 phosphorylated form III at 6 hr post-infection. We also observed degradation of IRF-3, by 24 hr after VSV infection (Fig. 6A). These findings are in agreement with studies conducted by tenOever et al. (102), who detected IRF-3 phosphorylated form III early (by 8 hr) with a shift back to isoform II occurring at later time points with VSV infection of A549 cells. A similar experiment with VSV conducted in HeLa cells yielded different results: we identified early phosphorylation of IRF-3 as a shift in band intensity from non-phosphorylated IRF-3 isoform I to isoform II, but isoform III was not detected (data not shown). This effect could be the result of various disruptions in cellular signaling pathways caused by the HPV18 (human papillomavirus 18) genes found within the HeLa genome (176). Indeed, HPV genes E6 and E7 are known to play a role in the suppression of IFN expression and signaling (177), and in vitro experiments by Ronco et al. (124) have demonstrated that HPV16 E6 interacts strongly with IRF-3 thereby inhibiting its ability to transactivate. However, only a moderate interaction was observed between HPV18 E6 and IRF-3, thus the effect of HPV18 E6 on the IRF-3 activation pathway was not
studied (124). Thus, although HPV genes expressed in HeLa cells may impact visible formation of IRF-3 form III (as assessed by SDS-PAGE), they do not appear to affect IRF-3's ability to transactivate target genes (as assessed by our RANTES-luc reporter constructs).

Once a positive model of IRF-3 phosphorylation in VSV infection was established, we proceeded to examine wtAd5-induced IRF-3 phosphorylation. As previously mentioned, HeLa cells are most often used for Ad studies since Ads grow in them rapidly and to high yield, and as such, the time course of Ad replication in this cell line has been well characterized (14, 15). Ad replication studies conducted by the Parks lab have demonstrated a similar time course of Ad replication in A549 cells (data not shown). Since the IFN signaling pathway is not disrupted in the A549 cell line, we used wtAd5-infected A549 cells to examine IRF-3 activity wherever possible.

In both wtAd5-infected HeLa (data not shown) and A549 cells, we determined that IRF-3 phosphorylation occurs late in the Ad life-cycle (24 hr post-infection), yet can occur early (6 hr post-infection) during infections at very high MOI (500 PFU/cell) (Fig. 6B). We detected wtAd5-induced IRF-3 phosphorylation as a shift in band intensity from predominantly non-phosphorylated IRF-3 isoform I to isoform II by SDS-PAGE. Importantly, we established that the shifting pattern we observed upon wtAd5 infection was indeed due to phosphorylation by demonstrating that the majority of the upper IRF-3 band was sensitive to phosphatase treatment (Fig. 7). Thus, Ad infection of a cell does result in a change in the phosphorylation status of IRF-3. It is conceivable that additional post-translational modifications to the IRF-3 protein such as SUMOylation or mono-ubiquitination could account for the portion of IRF-3 in the upper-band that was still visible after phosphatase treatment. Simple experiments involving lysate incubation with inhibitors
of the SUMOylation or ubiquitination pathways would provide further insight into this possibility.

Although we identified wtAd5-induced IRF-3 phosphorylation as a shift in band intensity from predominantly non-phosphorylated IRF-3 isoform I to isoform II, we were not able to detect IRF-3 phosphorylated form III or IV. Studies by Collins et al. (175) showed a similar phosphorylation pattern upon infection of cells by another DNA virus, HSV. Comparing the IRF-3 phosphorylation patterns they observed in response to infection by a number of different viruses, they determined that hyper-phosphorylation of IRF-3 is virus and cell-type dependent and ISG induction - a common indicator of IRF-3 activation - can occur without visible levels of hyper-phosphorylated IRF-3. As such, it appears as though hyper-phosphorylation is not a perfect marker of IRF-3 activation, but is most likely representative of the cell’s response to strong RNA virus replication (175). Since Ad is a DNA virus, it is perhaps not surprising that we were unable to detect phosphorylated form III upon wtAd5 infection.

WtAd5 immunomodulatory genes interfere with IRF-3 phosphorylation

Intriguingly, we observed a greater proportion of phosphorylated IRF-3 at lower MOI (24 hr) in cells infected with an E1^ΔE3Ad (Fig. 8) than in those infected with wtAd5 (Fig. 6B). Therefore, it appears as though the proteins encoded by genes within the E3 region may act to reduce IRF-3 phosphorylation in the infected cell. The E3 genes are most often deleted from Ad vectors used for gene therapy, and are not essential for replication in cultured cells (5). As previously mentioned, much of the Ad E3 gene region encodes for viral immunoregulatory genes that work to prevent the infected cell from being targeted and prematurely killed by the immune system during acute and latent infection (5). Various
functions have been attributed to proteins encoded in the E3 regions including inhibition of peptide presentation by class I MHC, and cell death by TNFα-, Fas-, or TRAIL (TNF-related apoptosis-inducing ligand)-induced mechanisms of cytolysis (178). Specifically, AdE3/10.4K and AdE3/14.5K transmembrane proteins form the receptor internalization and degradation (RID) complex which downregulates a specific set of cell surface receptors including the TNF receptor (TNFR) and family members Fas and TRAIL receptor (TRAIL-R) (179). In vitro, the RID complex inhibits TNFα-induced chemokine production and NFκB activation by downregulating cell surface levels of TNFR-1 (180-182). It is possible that E3 proteins could function in much the same way to target upstream signaling events in the pathway to IRF-3 phosphorylation in order to inhibit IRF-3 activation. Indeed, many RNA viruses have acquired functions to target different steps of the innate immune response, and a common tactic of RNA viruses involves the production of antagonists of the IFN response (183, 184). Viral proteins that specifically prevent IRF-3 activation pathways have been identified recently in the RSV genome (nonstructural (NS) proteins) as well as in the rabies virus (RV) genome (phosphoprotein (P)) (183, 184). Once the mechanism of IRF-3 activation in Ad infection has been elucidated, it is possible that proteins involved in indirectly targeting IRF-3 activation as well as IRF-3 specific antagonists may be revealed. It would not be surprising to find proteins such as these encoded within the Ad E3 gene region.

WtAd5-induced IRF-3 phosphorylation is dependent on viral replication

Interestingly, wtAd5-induced phosphorylation of IRF-3 occurs late during infection and coincides with the peak of Ad DNA replication (24 hr post-infection). Data from two
separate experiments (Figs. 9, 10) demonstrated that IRF-3 phosphorylation upon wtAd5 infection is dependant on virus replication. Our experiments did not establish if DNA replication without viral gene expression is required for IRF-3 phosphorylation upon wtAd5 infection. It would be interesting to determine if IRF-3 phosphorylation is dependent on the expression of viral proteins such as DNA polymerase, which are involved in viral DNA replication and are expressed early in the Ad life cycle.

There are a number of other possible mechanisms the cell may use to detect Ad5 infection/replication that could result in IRF-3 phosphorylation. First, the presence of small sections of replicated Ad DNA triggers DNA repair responses, specifically DNA-PK, a protein involved in sensing DNA damage and inducing proteins involved in DNA repair (185). DNA-PK is also known to directly phosphorylate IRF-3 near the nuclear export sequence on residue Thr$^{135}$, causing IRF-3 to be retained in the nucleus and triggering a downregulation in IRF-3 proteolysis which is important for maximizing the duration of the response (96, 101). Of course, nuclear retention is also critical for the induction of genes involved in the interferon response. Upon wtAd5 infection, we did not observe phosphorylation at Thr$^{135}$ (Fig. 12). This observation may be explained by the presence of proteins, encoded in the Ad5 E4 gene region, which directly bind to and inhibit DNA-PK (186, 187). Therefore, if a minor portion of DNA-PK escapes inhibition by Ad E4 proteins, IRF-3 phosphorylation is possible.

A second mechanism by which Ad infection may lead to IRF-3 phosphorylation is through the detection of dsRNA within the cell. Most RNA viruses produce dsRNA as part of their natural replicative cycle, and it is this dsRNA that is recognized in the infected cell and ultimately leads to IRF-3 activation. Cellular receptors for dsRNA within the cell include PAMP receptors such as TLR-3, and cytoplasmic pattern recognition receptors such
as RIG-I (128, 129). The role of RIG-I and TLR-3 in dsRNA recognition are cell-type dependent, however, both are key activators of the IRF-3 activation pathway (130, 131). During late adenoviral transcription, dsRNA is produced as a consequence of transcription occurring on both strands of the viral DNA (14). Therefore, it is possible that the dsRNA produced late in Ad infection could be detected by the cell, resulting in late IRF-3 activation.

Finally, studies with DNA viruses human CMV and HSV type I have demonstrated that even in the absence of virally produced dsRNA, IRF-3 is still activated, suggesting that IRF-3 activation may occur through recognition of an alternative component of the viral life cycle (104). While virus internalization is required for HSV-mediated activation of IRF-3, in CMV infection, binding to the cell is sufficient (103, 104). Indeed, IRF-3 is activated when cells are incubated with purified CMV attachment protein, gB (188). In addition, recent studies by tenOever et al. (189) demonstrated that in Measles virus (RNA virus) infection, IRF-3 activation is dependent on replication at low MOI and occurs through direct binding of IRF-3 with nucleocapsid (N) protein. Therefore, the detection of Ad proteins by the cell could be an alternative mechanism by which IRF-3 is activated within the infected cell.

*Primary target for wtAd5-induced IRF-3 phosphorylation is a novel residue(s)*

Extensive studies with RNA viruses have determined that phosphorylation of the IRF-3 protein can occur in four different regions. Within the amino terminus, residues Thr<sup>135</sup> and Ser<sup>188</sup> are targets for phosphorylation by DNA-PK and a member of the MAPK family, respectively. While it is recognized that phosphorylation of Thr<sup>135</sup> leads to nuclear retention and phosphorylation of Ser<sup>188</sup> occurs in response to stress and DNA damage, little else is known about the exact functional implication of N-terminal phosphorylation (96, 101). Conversely, phosphorylation of residues within the C-terminal region of IRF-3 is indicative
of IRF-3 activation, and occurs upon infection by many viruses (96, 101, 105, 109, 110). Multiple experiments conducted by Mori et al. and Servant et al. using SeV have narrowed the most probable phosphorylation residues to Ser\textsuperscript{386} (108) or Ser\textsuperscript{396} (99), however, the exact phosphorylation site required for virus-induced IRF-3 activation remains unclear.

Our data demonstrates that mutation of the C-terminal amino acids previously associated with IRF-3 activation by RNA viruses (Ser\textsuperscript{386} and Ser\textsuperscript{396}), or other residues in the C-terminus that have been shown to be phosphorylated, does not significantly alter the pattern of IRF-3 phosphorylation upon wtAd5 infection (Fig. 12). This observation suggests that the primary target for Ad-induced phosphorylation is not in the C-terminus. However, Collins et al. (175) have suggested that only a minor proportion of IRF-3 needs to be activated (i.e. phosphorylation in the C-terminus) in order for a full interferon response to occur, and that this may not be detectable as a visible change in IRF-3 phosphorylation status by SDS-PAGE. Nevertheless, our data using reporter constructs containing the RANTES promoter (discussed below) suggest that IRF-3 is indeed activated.

Infection of cells with Ad appears to induce phosphorylation of IRF-3 at a novel residue. Transfection of a plasmid encoding a mutant IRF-3 containing non-phosphorylatable residues at all previously-identified phosphorylation sites did not yield a different pattern or ratio of type I to type II IRF-3 compared with un-mutated IRF-3 (Fig. 12). Recent experiments in our lab have determined that the novel phosphorylation residue is Ser\textsuperscript{173}, which is located within the N-terminus of the protein (R. Parks, personal communication). Although the function of N-terminal phosphorylation is not known, several possibilities have been suggested. Phosphorylation of the N-terminus may cause a conformational change in IRF-3 structure, making the C-terminal Ser-Thr residues accessible for the phosphorylation by VAK (101, 126). As the mechanism of IRF-3 activation and the
identity of the VAK responsible depend on the virus/stimuli, and it is likely that multiple signaling pathways and kinases lead to activation of IRF-3 (96, 99), perhaps phosphorylation of this novel residue is required for C-terminal phosphorylation that leads to IRF-3 activation during Ad infection.

WtAd5-induced RANTES expression occurs late and is replication-dependent

The data presented above clearly demonstrates that IRF-3 is phosphorylated upon wtAd5 infection. However, we did not observe IRF-3 forms III or IV, which are commonly associated with true activation of IRF-3, at least for RNA viruses (101, 108). Since detection of C-terminal phosphorylation or the presence of IRF-3 phosphorylation isoforms III or IV are not perfect methods of examining of IRF-3 activation (175), we investigated wtAd5-induced IRF-3 activation by examining its role in the induction of RANTES. The RANTES gene is a direct target for IRF-3 activation (100, 148, 149, 163). Our experiments suggest that wtAd5-induced RANTES expression, like IRF-3 phosphorylation, occurs late in the Ad life cycle (Fig. 13) and is dependent on Ad replication (Fig. 15). Furthermore, phosphorylation of residues 382-414 within the C-terminus of IRF-3 is important in wtAd5-induced RANTES expression since expression of a dominant-negative form of IRF-3 (mutated in these residues) reduced RANTES activation (Fig. 18D). Finally, in the wtAd5-infected cell, IRF-3 is required for full induction of RANTES expression (Figs. 16, 17), as shown by RANTES promoter/deletion mutation analysis. Taken together, our data suggests that IRF-3 is indeed important in the induction of inflammatory cytokines/chemokines in Ad-infected cells.

Previous in vivo studies have demonstrated an induction of RANTES expression in both lung (alveolar macrophages) (66) and liver tissue (34) within hours of Ad vector
transduction in mice. This early induction of RANTES in vivo, however, may reflect the activation of immune cells, such as Kupffer cells (resident macrophage of the liver), which are the prime target for Ad infection after systemic delivery in mice (13, 34). Since these are immune cells, they are likely to respond faster than other cell types. Indeed, we have observed IRF-3 phosphorylation by 2 hr following wtAd5 infection of macrophage-like differentiated THP-1 cells (data not shown).

Early induction of RANTES expression has also been observed after Ad vector transduction in HeLa cells, primary kidney epithelial cells, and in mouse insulinoma cell line TGP61 (34, 75). In addition, Hartman et al. (80) have shown recently through micro-array analysis, that many of the early genes induced in ΔE1/E3Ad-infected MEFs have IRF-7 binding sites. Although IRF-7 and IRF-3 do not bind the same sequences, IRF-7 function is coupled with late amplification phases of gene activation that follows the immediate-early phase associated with IRF-3 function (141, 145). Thus, IRF-3 activation is absolutely required for IRF-7 function. Furthermore, through measurement of cytokine secretion by Ad-infected MEFs, Hartman et al. (80) confirm that the expression of several genes they identified as Ad-responsive also translated into increased protein expression/secretion. Indeed, RANTES showed a high level of up-regulation at the protein level starting 6 hr post-infection (80).

In our study, we used luciferase reporter constructs to examine RANTES expression in wtAd5-infected HeLa cells. We were intrigued to find that RANTES expression occurred late in infection (24 hr post-infection) contrary to the early Ad5 vector-induced RANTES expression previously observed using similar methods (6 hr post-infection) (75). There are limitations to transfection-based assays, as they represent only simulated systems where plasmid DNA exists in an artificial configuration (i.e. not properly chromatinized) with
variable copy numbers that influence results (190). However, we repeated our experiments multiple times and obtained similar results.

In order to ensure complete transduction efficiency, all previously published studies were based on experiments using Ad5 vectors at very high MOI (31, 66, 75, 80). Indeed, Muruve et al. (34) observed less efficient hepatocyte-mediated cytokine/chemokine induction when mice were injected with ΔE1-E3-defective Ad5 vectors at lower titers. In our experiments, we used a much lower MOI. When we did use higher MOI, we observed RANTES induction earlier (6 hr - Fig.6). Furthermore, unlike the other studies, our experiments were conducted with wtAd5 and thus contained both E1 and E3 regions. As previously discussed, immunoregulatory proteins in the E3 region appear to interfere with IRF-3 phosphorylation (Fig.8), therefore it is possible that in our experiments with wtAd5, early RANTES expression also may have been hampered by actions of the E3 proteins.

**Future Directions**

Our data suggests IRF-3 is indeed activated upon wtAd5 infection, however in order to directly confirm these results, ChIP (Chromatin Immuno-precipitation) analysis of IRF-3 binding to ISG promoters should be performed. In addition, several other steps along the IRF-3 activation pathway could be studied including IRF-3 homo-dimerization, migration of IRF-3 from the cytoplasm to the nucleus and binding of IRF-3 with CBP. Simple experiments could be devised to study these steps: analysis of IRF-3 migration though non-denaturing PAGE (IRF-3 dimerization), immuno-precipitation experiments (IRF-3/CBP binding) and immuno-cytochemistry (localization of IRF-3). However, as only a minor proportion of IRF-3 needs to be activated in order for a full interferon response to occur,
these steps along the IRF-3 activation pathway may be difficult to observe and not easily detected (175).

Further analysis of Ser^{173}, the IRF-3 amino terminal residue primarily phosphorylated upon wtAd5 infection, is another important priority for future studies. Uncovering the pathways involved in this phosphorylation event will help to determine the identity of the stimulus and perhaps the functional implication of this specific phosphorylation event. It would also be very interesting to determine if this residue is phosphorylated in response to RNA viruses and other DNA viruses such as HSV and CMV.

At this time, the mechanism of wtAd5-induced IRF-3 activation, including the stimulus responsible for starting the activation pathway and the identity of the VAK responsible for C-terminal phosphorylation that leads to IRF-3 activation, remains unknown. As previously mentioned, there are at several mechanisms by which the cell could detect Ad5 infection/replication that could result in IRF-3 phosphorylation and subsequent activation, including the recognition of small sections of replicated Ad DNA, dsRNA produced during late Ad transcription, or Ad protein expression. Once the stimulus has been determined it will point to an activation pathway for IRF-3. It would also be important to determine if the mechanism of IRF-3 activation differs upon infection by other Ad serotypes. For example, the rate and timing of infection by Ad7 is much different than Ad5 and, indeed, preliminary experiments have suggested that IRF-3 phosphorylation occurs early in Ad7-infected cells.

As discussed above, the immunoregulatory proteins encoded in the Ad E3 gene region appear to interfere with IRF-3 phosphorylation, and may inhibit wtAd5-induced early RANTES expression. Further studies focusing on the effects of the E3 proteins are therefore in order. An examination of the timing and occurrence of specific steps in the IRF-3
activation pathway (i.e. IRF-3 homo-dimerization, localization, complex formation with CBP, direct binding to ISRE on ISG promoters) in response to infection by ΔE1-E3-defective Ad or E1*ΔE3Ad could reveal additional immunoregulatory functions of the E3 gene region that may interfere directly or indirectly with IRF-3 and the pathways which it activates.

Recently, micro-array studies by Hartman et al. (70) have demonstrated a potent cellular transcriptome response in murine liver samples following intravenous administration of high-titer Ad vectors. Using the same methods, they have also demonstrated that the early genes induced in ΔE1/E3Ad-infected MEFs have IRF-7 binding sites (80). Additional micro-array analysis focusing on the identification of IRF-3 binding sites following wtAd5 infection could reveal Ad-specific transcription factor functions of IRF-3 that are unknown at this time.

Finally, once further insights have been made in the areas mentioned above, the next step would be to characterize wtAd5 activation of IRF-3 and innate immune responses in vivo. There are significant differences observed between the innate immune response to the Ad5 virus in vitro compared to those seen in vivo, and no study has attempted to characterize the in vivo IRF-3 activation pathway in response to wtAd5 infection.

With information from in vivo studies, a greater understanding of the innate immune response to Ad would be achieved, allowing for insights into novel methods that could be used to combat severe Ad diseases as well as innovative strategies for the development of nontoxic Ad vectors for gene therapy.
Recent developments

Since this thesis was originally submitted, three papers investigating the innate immune response to Ad have been published. Zhu et al. (191) demonstrated that the innate immune response to ΔE1 and ΔE3Ad5 vectors is mediated by both TLR-dependent and independent pathways in different types of dendritic cells (DC). While infection of conventional DCs generates a TLR-independent immune response through cytosolic detection of Ad DNA, infection of plasmacytoid DCs, elicits an immune response via TLR-9 signaling through MyD88 (191). Equally, Cerullo et al. (192) provided evidence that TLR-9 triggers an innate immune response to hdAd in primary macrophages. Conversely, Nociari et al. (193) have established that upon ΔE1/E3Ad5 infection of murine bone marrow derived macrophage (BMMO) or dendritic cells (BMDC), IRF-3 activation results from a signaling cascade that is triggered by the recognition of viral DNA by an intracellular sensor and not TLR-9. These studies demonstrate the complexity and diversity of the innate immune response to Ad5-based vectors in cells of the immune system. Future experiments in non-immune cells will likely demonstrate equally interesting results.

Conclusions

Our study is the first to underline the importance of IRF-3 for full induction of RANTES expression upon wtAd5 infection, suggesting that IRF-3 plays a significant role in the establishment of the antiviral state in wtAd5-infected cells, and indirectly implying that IRF-3 is indeed activated upon wtAd5 infection. Furthermore, we observed that although mutation of amino acids previously associated with IRF-3 activation by RNA viruses (Ser386 and Ser396) does not significantly alter the pattern of IRF-3 phosphorylation upon wtAd5
infection, over-expression of a dominant-negative form of IRF-3 containing these mutations causes a decrease in RANTES expression. This data suggests that phosphorylation of these residues is also important in wtAd5-induced IRF-3 activation. In addition, we demonstrated that the primary target for IRF-3 phosphorylation in wtAd5 infection is a novel amino terminal residue. Finally, we determined that wtAd5-induced IRF-3 phosphorylation and subsequent activation occurs late in Ad infection (24 hr post-infection) and is dependent on the ability of the cell to detect virus replication. As our study is the first to examine the innate immune response to wtAd5 and Ad5-based vectors with respect to IRF-3 activation in vitro, our results have begun to map a major signaling pathway used by many viruses to combat infection, thus bringing new insight into the early immune response to wtAd infection and gene therapy vectors.
REFERENCES


70. Hartman, Z.C., A. Kiang, R.S. Everett, D. Serra, X.Y. Yang, T.M. Clay, and A. Amalfitano. 2006. Adenovirus infection triggers a rapid, MyD88 regulated,
transcriptome response critical to acute phase and adaptive immune responses in vivo. *Journal of virology*


Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.


APPENDIX A: Reagents

Tissue Culture

- MEM (Modified Eagle Medium) (Sigma)
- DMEM (Dulbecco Modified Eagle Medium) (Sigma)
- DMEM-PBS (Phosphate Buffered Saline) (Sigma)
- MEM/DMEM with 10% FBS (Fetal Bovine Serum):
  500mL MEM/DMEM (Sigma)
  50mL FBS (10%) (Invitrogen)
  5mL antibiotic/antimycotic (1%) (Invitrogen)
  5mL GlutaMax (1%) (Invitrogen)
- 10x Citric Saline:
  100.66g KCl (1.35M)
  44.11g sodium citrate (150mM)
  up to 1L H₂O
  autoclave 45min at 121°C
- 1x Citric Saline:
  50mL 10x Citric Saline
  up to 500mL H₂O
- 5x Trypsin (Invitrogen)
- 1x Trypsin:
  4mL 5x Trypsin (Invitrogen)
  up to 40mL DMEM-PBS (Sigma)
- Lipofectamine 2000 (Invitrogen)

Lysis Buffer

- RIPA (RadioImmunoPrecipitation Assay) Buffer (Phosphatase Treatment Exp.)
  250μL 1M Tris-HCl pH 7.4 (50mM)
  150μL 5M NaCl (150mM)
  50μL Nonidet P-40 (1%)
  500μL Glycerol (10%)
  50μL 0.5M EDTA (5mM)
  5μL aprotinin (5μg/mL)
  5μL leupeptin (5μg/mL)
  50μL 100mM PMSF (phenylmethylsulphonylfluoride) (1mM)
  up to 5mL with H₂O, filter sterilize
Western Blotting

- **2x Denaturing Sample Buffer:**
  2.5mL 0.5M Tris-HCl pH 6.8
  25mL Glycerol (25%)
  10mL 20% SDS (2%)
  0.01g bromophenol blue
  up to 100mL H₂O

- **10% APS:**
  0.1g ammonium persulfate
  up to 1mL H₂O

- **2x Separating Gel Buffer:**
  18.164g Tris (750mM)
  0.4g SDS (0.2%)
  up to 200mL H₂O
  adjust pH to 8.8

- **Separating Gel Solution:**

<table>
<thead>
<tr>
<th>Reagents</th>
<th>7.5% SDS-PAGE</th>
<th>10% SDS-PAGE</th>
<th>12% SDS-PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>ddH₂O 2.5mL</td>
<td>2.0mL</td>
<td>1.0mL</td>
<td></td>
</tr>
<tr>
<td>2x Sep Gel Buffer</td>
<td>5.0mL</td>
<td>5.0mL</td>
<td>5.0mL</td>
</tr>
<tr>
<td>30% Acrylamide</td>
<td>2.5mL</td>
<td>3.0mL</td>
<td>4.0mL</td>
</tr>
<tr>
<td>10% APS</td>
<td>100μL</td>
<td>100μL</td>
<td>100μL</td>
</tr>
<tr>
<td>TEMED</td>
<td>10μL</td>
<td>10μL</td>
<td>10μL</td>
</tr>
</tbody>
</table>

- **2x Stacking Gel Buffer:**
  6.056g Tris (250mM)
  0.4g SDS (0.2%)
  up to 200mL H₂O
  adjust to pH to 6.8

- **Stacking Gel Solution:**
  2mL H₂O
  3mL 2x Stacking Gel Buffer
  1mL 30% Acrylamide
  100 μL 10% APS
  10 μL TEMED.

- **1x Running Buffer:**
  6.08g Tris (50mM)
  28.8g glycine (1.44%)
  2.0g SDS (0.1%)
  up to 2L H₂O

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
- 1x Transfer Buffer:
  5.82g Tris (48mM)
  2.93g glycine (0.293%)
  3.75mL 10% SDS (0.0375%)
  200mL MeOH (20%)
  up to 1L H₂O.

- 0.1% TBST (Tris Buffered Saline with Tween20):
  30mL 5M NaCl (150mM)
  10mL 1M Tris-HCl pH8.0 (10mM)
  1mL TWEEN-20 (0.1%)
  up to 1L H₂O

- 5% Milk Blocking Solution:
  1g skim milk powder
  up to 20mL with 0.1% TBST

**Cloning**

**Bacterial Amplification of Cloned DNA**

- LB Broth:
  20g LB Broth up to 1L H₂O
  autoclave 45min at 121°C

- LB Broth with Agar:
  500mL LB Broth
  7.5g Agar

- LB Broth with Agar and AMP:
  500mL LB Broth
  500 µL 50mg/mL Ampicillin (50 µg/mL)

- 30% Glycerol:
  30mL Glycerol,
  up to 100mL H₂O
Plasmid DNA Preparation (as in Bimboim and Dolly (172) and Sambrook et al. (173))

- Solution I:
  4.5g dextrose (50mM)
  12.5mL 1M Tris-HCl pH 7.5 (250mM)
  10mL 0.5M EDTA pH 8.0 (10mM)
  up to 500mL H₂O
  adjust pH to 8.0, filter sterilize

- Solution II:
  200µL 10M NaOH (200mM)
  500µL 20% SDS (1%)
  up to 10mL H₂O

- Solution III:
  147.21g potassium acetate
  57.5mL glacial acetic acid (11.5%)
  up to 500mL H₂O

- 10x SSC (standard saline citrate):
  87.66g NaCl
  13.23g sodium citrate
  up to 1L H₂O

- 0.1x SSC:
  5mL 10x SSC
  up to 500mL H₂O

RbCl Competent Cells (as in (171))

- 2x YT (Yeast-Tryptone):
  8g Tryptone-peptone
  5g yeast extract
  2.5g NaCl
  up to 500mL H₂O
  adjust to pH 7.0, filter sterilize

- RF1:
  1.2g RbCl (100mM)
  0.99g MnCl₂.4 H₂O (50mM)
  3mL 1M potassium acetate (30mM)
  0.15g CaCl₂.2H₂O (10mM)
  15mL Glycerol (15% w/v)
  up to 100mL H₂O
  adjust to pH 5.8 with 0.2M acetic acid
- 1M Potassium Acetate:
  9.82g potassium acetate,
  up to 100mL H₂O
  adjust pH to 7.5 with 0.2M acetic acid.

- RF2:
  2mL 0.2M MOPS (10mM)
  0.12g RbCl (10mM)
  1.1g CaCl₂.2H₂O (75mM)
  15mL Glycerol (15% w/v)
  up to 100mL H₂O
  adjust to pH 6.8 with 2N NaOH

- 0.5M MOPS (3-(N-morpholino)propanesulfonic acid:
  10.46g MOPS
  up to 100mL H₂O
  adjust to pH 6.8 with 2N NaOH

**Agarose Gel Electrophoresis**

- 50x TAE (Tris-AceticAcid-EDTA):
  242g Tris
  57mL acetic acid (5.7%)
  100mL 0.5M EDTA (50mM)
  up to 1L H₂O

- 1x TAE:
  80mL 50x TAE
  up to 4L H₂O

- Agarose gel (1.2%)
  1.2g agarose (1.2%)
  up to 100mL 1x TAE
  1μL ethidium bromide

- 6x Loading Buffer:
  40g sucrose (40%)
  0.125g bromophenol blue (0.125%)
  20mL 0.5M EDTA pH 8.0 (0.1M)
  up to 100mL H₂O

- Loading Buffer + RNase:
  1.5mL 6x Loading Buffer
  10μL 50mg/mL RNase
**General Chemicals and Reagents**

- **1M Tris-HCl pH8.0:**
  - 121.14g Tris
  - up to 1L H₂O
  - adjust to pH 8.0 with HCl

- **0.5M EDTA:**
  - 146.13g EDTA (ethylenediaminetetraacetic acid)
  - up to 1L H₂O
  - adjust to pH 8.0 with HCl

- **TE: Tris-EDTA**
  - 10mM Tris-HCl pH8.0
  - 1mM EDTA pH8.0

- **10M NaOH:**
  - 39.978g NaOH
  - up to 100mL H₂O

- **5M NaCl:**
  - 146.11g NaCl
  - up to 500mL H₂O.

- **20% SDS:**
  - 100g SDS (sodium dodecyl sulfate)
  - up to 500mL H₂O
APPENDIX B: Plasmids

List of plasmids created for this project

1. Plasmids containing IRF-3 mutations:

Note: The original commercially purchased IRF-3 cDNA sequence contained an insert that placed the carboxy terminus of the protein out of frame. This error was not discovered until many derivative plasmids had been already generated.

Incorrect Plasmids:

pBS-IRF3

This plasmid contains the incorrect IRF-3 sequence in a pBluescriptKS+ (Stratagene) vector. To construct this plasmid, IRF-3 cDNA was amplified using overlap PCR with the following primers:

5'-CCG TGA TCA GCC ATG GGA ACC CCA AAG CCA CGG ATC CTG -3' (forward)
5'-CCG GAA TTC TCA GCT CTC CCC AGG GCC CTG GAA ATC -3' (reverse)

Amplified IRF-3 cDNA was then ligated into EcoRI/ApnI-digested pBluescriptKS+.

pBS-Flag-IRF3

This plasmid contains the incorrect Flag-tagged IRF-3 sequence in a pBluescriptKS+ (Stratagene) vector. To construct this plasmid, a ~36 bp oligonucleotide sequence containing the FLAG tag and flanked by NcoI restriction sites was annealed and ligated into NcoI-digested pBS-IRF3. The oligonucleotide sequences used are as follows:

5'-CAT GCT TGA TTA CAA GGA TGA CGA CGA TA A GCT TGG -3' (forward)
5'-GAA CTA ATG TTC CTA CTG CTG CTA TTC GAA CCG TAC- 3' (reverse)

pcDNA3-Flag-IRF3

This plasmid contains the incorrect Flag-tagged IRF-3 sequence in a pcDNA3 (Invitrogen) vector. To construct this plasmid, a ~1.3 kb EcoRI/KpnI fragment containing the entire IRF-3 open reading frame, was excised from pBS-Flag-IRF3 and cloned into EcoRI/KpnI-digested pcDNA3.
**pBS-Flag-IRF3-T135A**  
*(see pKC23 for corrected plasmid)*

This plasmid contains the incorrect Flag-tagged IRF-3 sequence with the correct T135A mutation in a pBluescriptKS+ vector. To construct this plasmid, pBS-Flag-IRF3 was amplified using overlap PCR with the following primers containing the T135A mutation:

5'-GCG ACT AGT GAT GCC CAG GAA GAC ATT CTG GAT G-3' (forward)  
5'-GCG ACT AGT ACT GCC TCC ACC ATT GGT GTC CGG AG-3' (reverse)

Linear amplified pBS-Flag-IRF3 (containing the T135A mutation) was self-ligated after SpeI digestion.

**pBS-Flag-IRF3-S188A**  
*(see pKC24 for corrected plasmid)*

This plasmid contains the incorrect Flag-tagged IRF-3 sequence with the correct S188A mutation in a pBluescriptKS+ vector. To construct this plasmid, pBS-Flag-IRF3 was amplified using overlap PCR with the following primers containing the S188A mutation:

5'-GCG CCT AGG GCC CGC TGA GAA CCC ACT GAA GCG GCT G-3' (forward)  
5'-GCG CCT AGG TTT GGG AAG GGA GTG GGA TTG TC-3' (reverse)

Linear amplified pBS-Flag-IRF3 (containing the S188A mutation) was self-ligated after AvrII digestion.

**pBS-Flag-IRF3-T135A/S188A**  
*(see pKC16 for corrected plasmid)*

This plasmid contains the incorrect Flag-tagged IRF-3 sequence with the correct T135A and S188A mutations in a pBluescriptKS+ vector. To construct this plasmid, a ~180 bp XmnI fragment containing the S188A mutation was excised from pBS-Flag-IRF3-S188A and cloned into XmnI-digested pBS-Flag-IRF3-T135A.

**pBS-Flag-IRF3-2A**

This plasmid contains the incorrect Flag-tagged IRF-3 sequence with the correct 2A mutation in a pBluescriptKS+ vector. To construct this plasmid, a ~177 bp oligonucleotide sequence containing the 2A mutation and flanked by *Bsu36I/Sse8387I* restriction sites was annealed and ligated into *Bsu36I/Sse8387I*-digested pBS-Flag-IRF3. The oligonucleotide sequences used are as follows:

5'-TCA GGG CCT TGG TAG AAA TGG CCC GGG TAG GGG GTG CCG CAG CAC TGG AGA ATA CTG TGG ACC 'TGC ACA TTT CCA ACA GCC ACC CAC TCT CCC TCA CCT CCG ACC AGT ACA AGG CTT ACC 'TGC A-3' (forward)
pBS-Flag-IRF3-5A

This plasmid contains the incorrect Flag-tagged IRF-3 sequence with the correct 5A mutation in a pBluescriptKS+ vector. To construct this plasmid, a ~117 bp oligonucleotide sequence containing the 5A mutation and flanked by *Bsu36I/Sse8387I* restriction sites was annealed and ligated into *Bsu36I/Sse8387I*-digested pBS-Flag-IRF3. The oligonucleotide sequences used are as follows:

5'-TCA GGG CCT TGG TAG AAA TGG CCA GGG TAG GGG GTG CCA TGG CCA ACG CCC ACC ACC TCG CCC TCG CCG ACC AGT ACA AGG CCT ACC TGG A-3' (forward)

5'-GGT AAG CCT TGT ACT GGT CGG AGG TGA GGG AGA GTG GGT GGC TGT TGG AAA TGT GCA GGT CCA CAG TAT TCT CCA GTG CTG CGG CAC CCC CTA CCC GGG CCA TTT CTA CCA AGG CCC-3' (reverse)

pBS-Flag-IRF3-2A/5A

This plasmid contains the incorrect Flag-tagged IRF-3 sequence with the correct 2A/5A mutation in a pBluescriptKS+ vector. To construct this plasmid, pBS-Flag-IRF3-5A was amplified using overlap PCR with the following primers containing the 2A mutation:

5'-GGC ACG CGT AGG GGG TGC CGC AGC CCT GGA GAA TAC TGT GGA CCT G-3' (forward)
5'-GCG ACG CGT GCC ATT TCT ACC AAG GCC CTG-3' (reverse)

Linear amplified pBS-Flag-IRF3-5A (containing the 2A mutation) was self-ligated after *MluI* digestion.

pcDNA3-Flag-IRF3-T135A

(see pKC25 for corrected plasmid)

This plasmid contains the incorrect Flag-tagged IRF-3 sequence with the incorrect T135A mutation in a pcDNA3 vector. To construct this plasmid, a ~1.3 kb *EcoRI/KpnI* fragment containing the entire IRF-3 open reading frame and thus including the T135A mutation, was excised from pBS-Flag-IRF3-T135A and cloned into *EcoRI/KpnI*-digested pcDNA3.
pcDNA3-Flag-IRF3-S188A
(see pKC26 for corrected plasmid)
This plasmid contains the incorrect Flag-tagged IRF-3 sequence with the correct S188A mutation in a pcDNA3 vector. To construct this plasmid, a ~1.3 kb EcoRI/KpnI fragment containing the entire IRF-3 open reading frame and thus including the S188A mutation, was excised from pBS-Flag-IRF3-S188A and cloned into EcoRI/KpnI-digested pcDNA3.

pcDNA3-Flag-IRF3-2A
(see pKC18 for corrected plasmid)
This plasmid contains the incorrect Flag-tagged IRF-3 sequence with the correct 2A mutation in a pcDNA3 vector. To construct this plasmid, a ~1.3 kb EcoRI/KpnI fragment containing the entire IRF-3 open reading frame and thus including the S188A mutation, was excised from pBS-Flag-IRF3-2A and cloned into EcoRI/KpnI-digested pcDNA3.

pcDNA3-Flag-IRF3-5A
(see pKC19 for corrected plasmid)
This plasmid contains the incorrect Flag-tagged IRF-3 sequence with the correct 5A mutation in a pcDNA3 vector. To construct this plasmid, a ~1.3 kb EcoRI/KpnI fragment containing the entire IRF-3 open reading frame and thus including the S188A mutation, was excised from pBS-Flag-IRF3-5A and cloned into EcoRI/KpnI-digested pcDNA3.

pcDNA3-Flag-IRF3-2A/5A
(see pKC20 for corrected plasmid)
This plasmid contains the incorrect Flag-tagged IRF-3 sequence with the correct 2A and 5A mutations in a pcDNA3 vector. To construct this plasmid, a ~1.3 kb EcoRI/KpnI fragment containing the entire IRF-3 open reading frame and thus including both the 2A and 5A mutations, was excised from pBS-Flag-IRF3-2A/5A and cloned into EcoRI/KpnI-digested pcDNA3.

pcDNA3-Flag-IRF3-T135A/S188A
(see pKC21 for corrected plasmid)
This plasmid contains the incorrect Flag-tagged IRF-3 sequence with the incorrect T135A and correct S188A mutations in a pcDNA3 vector. To construct this plasmid, a ~1.3 kb EcoRI/KpnI fragment containing the entire IRF-3 open reading frame and thus including both the T135A and S188A mutations, was excised from pBS-Flag-IRF3-T135A/S188A and cloned into EcoRI/KpnI-digested pcDNA3.
pcDNA3-Flag-IRF3-T135A/S188A/2A/5A
(see pKC22 for corrected plasmid)

This plasmid contains the incorrect Flag-tagged IRF-3 sequence with the incorrect T135A and correct S188A, 2A, and 5A mutations in a pcDNA3 vector. To construct this plasmid, a ~171 bp EcoRI/Bsu36I fragment containing the 2A and 5A mutations, was excised from pBS-Flag-IRF3-T135A/S188A and cloned into EcoRI/Bsu36I-digested pcDNA3-Flag-IRF3-T135A/S188A.
Correct Plasmids:

PBS-Flag-IRF3fix

This plasmid contains the correct Flag-tagged IRF-3 sequence in a pBluescriptKS+ (Stratagene) vector. To construct this plasmid, PBS-Flag-IRF3 was amplified using overlap PCR with the following primers:

5'-GCG AGA TCT GAT TAC CTT CAC GGA AGG AAG-3' (forward)
5'-GCG AGA TCT ACA ATG AAG GGC CCC AGG TC-3' (reverse)

These primers were created to prevent the 16 bp insert from being amplified (thus putting IRF-3 back in frame). Linear amplified PBS-Flag-IRF3 (without the 16 bp insert) was self-ligated after BglII digestion.

pcDNA3-Flag-IRF3fix

This plasmid contains the correct Flag-tagged IRF-3 sequence in a pcDNA3 (Invitrogen) vector. To construct this plasmid, a ~1.3 kb EcoRI/KpnI fragment containing the entire IRF-3 open reading frame, was excised from PBS-Flag-IRF3fix and cloned into EcoRV/KpnI-digested pcDNA3.

pKC16

This plasmid contains Flag-tagged IRF-3 with the T135A and S188A mutations in a pBluescriptKS+ vector. To construct this plasmid, a ~220 bp BbsI/BbsI fragment containing the S188A mutation was excised from pKC23 and cloned into BbsI-digested pKC24.

pKC18

This plasmid contains Flag-tagged IRF-3 with the 2A mutation in a pcDNA3 vector. To construct this plasmid, a ~200 bp XbaI/Bsu36I fragment containing the 2A mutation was removed from pcDNA3-Flag-IRF3-2A and cloned into XbaI/Bsu36I-digested pcDNA3-Flag-IRF-3, which contains the correct IRF-3 sequence.

pKC19

This plasmid contains Flag-tagged IRF-3 with the 5A mutation in a pcDNA3 vector. To construct this plasmid, a ~200 bp XbaI/Bsu36I fragment containing the 5A mutation was removed from pcDNA3-Flag-IRF3-5A and cloned into XbaI/Bsu36I-digested pcDNA3-Flag-IRF-3, which contains the correct IRF-3 sequence.
pKC20

This plasmid contains Flag-tagged IRF-3 with the 2A and 5A mutations in a pcDNA3 vector. To construct this plasmid, a ~200 bp XbaI/Bsu36I fragment containing the 2A and 5A mutations was excised from pcDNA3-Flag-IRF3-2A/5A and cloned into XbaI/Bsu36I-digested pcDNA3-Flag-IRF-3, which contains the correct IRF-3 sequence.

pKC21

This plasmid contains Flag-tagged IRF-3 with the T135A and S188A mutations in a pcDNA3 vector. To construct this plasmid, a ~1.3 kb EcoRI/KpnI fragment containing the entire IRF-3 open reading frame and thus including the T135A and S188A mutations, was excised from pKC16 and cloned into EcoRI/KpnI-digested pcDNA3.

pKC21b

This plasmid contains Flag-tagged IRF-3 with the T135A, S188A, 2A, and 5A mutations in a pBluescriptKS+ vector. To construct this plasmid, a ~216 bp XbaI/Bsu36I fragment containing the 2A and 5A mutations was removed from pKC20, and cloned into XbaI/Bsu36I-digested pKC16.

pKC22

This plasmid contains Flag-tagged IRF-3 with the T135A, S188A, 2A, and 5A mutations in a pcDNA3 vector. To construct this plasmid, a ~216 bp XbaI/Bsu36I fragment containing the 2A and 5A mutations was removed from pKC20, and cloned into XbaI/Bsu36I-digested pKC21.

pKC23

This plasmid contains Flag-tagged IRF-3 with the T135A mutation in a pBluescriptKS+ vector. To construct this plasmid, a ~731 bp HindIII/MscI fragment containing the T135A mutation was excised from pBS-Flag-IRF3-T135A, and cloned into HindIII/KpnI-digested pBS-Flag-IRF3, which contains the correct IRF-3 sequence.

pKC24

This plasmid contains Flag-tagged IRF-3 with the S188A mutation in a pBluescriptKS+ vector. To construct this plasmid, a ~731 bp HindIII/MscI fragment containing the S188A mutation was excised from pBS-Flag-IRF3-S188A, and cloned into HindIII/KpnI-digested pBS-Flag-IRF3, which contains the correct IRF-3 sequence.
pKC25

This plasmid contains Flag-tagged IRF-3 with the T135A mutation in a pcDNA3 vector. To construct this plasmid, a ~1.3 kb EcoRI/KpnI fragment containing the entire IRF-3 open reading frame and thus including the T135A mutation, was excised from pKC23 and cloned into XbaI/Bsu36I-digested pcDNA3.

pKC26

This plasmid contains Flag-tagged IRF-3 with the S188A mutation in a pcDNA3 vector. To construct this plasmid, a ~1.3 kb EcoRI/KpnI fragment containing the entire IRF-3 open reading frame and thus including the S188A mutation, was excised from pKC24 and cloned into XbaI/Bsu36I-digested pcDNA3.
2. RANTES Promoter Constructs:

The following plasmids were a generous gift from Dr. D.A. Muruve (University of Calgary, Calgary, Alberta). They were generated from the pGL2-RANTES(-900) plasmid, originally constructed by Nelson et al. (160). pGL2-RANTES(-900) consists of a 900 bp sequence upstream of the transcriptional start site of the human RANTES gene (GenBank accession no. S64885) cloned into a pGL2 Basic reporter vector (Promega). See Fig. 18A and 19A for a detailed representation of the human RANTES promoter and the deletional mutants used in this project.

pGL2-RANTES(-296)

This plasmid contains a deletional mutant of pGL2-RANTES(900) at position –296 (296 nucleotides into the immediate upstream region of the promoter region). This deletional mutant was constructed by PCR (Bowen et al. (75)), and contains both IRF-3 and NK-κB binding sites upstream of the RANTES promoter.

pGL2-RANTES(-181)

This plasmid contains a deletional mutant of pGL2-RANTES(900) at position –181 (181 nucleotides into the immediate upstream region of the promoter region). This deletional mutant was constructed in a 5' to 3' restriction enzyme digest using SacI (Bowen et al. (75)), and contains both IRF-3 and NK-κB binding sites upstream of the RANTES promoter.

pGL2-RANTES(-90)

This plasmid is a deletional mutant of pGL2-RANTES(900) at position –90 (90 nucleotides into the immediate upstream region of the promoter region), thereby removing the IRF-3 binding site upstream from the RANTES promoter. This deletional mutant was constructed by PCR (Bowen et al. (75)).

pGL2-RANTES(-296mutKB)

This plasmid is a deletional mutant of pGL2-RANTES(900) at position –296, which also contains site-directed mutagenesis of the proximal NK-κB binding sites at positions –54 and –39 bp (upstream of the transcriptional start site), thereby removing the ability for NK-κB to bind at these sites. This plasmid was constructed using a site-directed mutagenesis kit (see Bowen et al. (75)).
pKC27

This plasmid contains a fragment of pGL2-RANTES(-181) cloned into a pBluescript KS+ vector. To construct this plasmid, a ~357 bp XbaI fragment containing the IRF-3 binding sites upstream of the RANTES promoter, was removed from pGL2-RANTES(-181) and cloned into XbaI-digested pBluescript KS+.

pKC28

This plasmid contains a mutated fragment of pGL2-RANTES(-181) cloned into a pBluescript KS+ vector. To construct this plasmid, a ~63 bp oligonucleotide flanked by BspEI/PflMI restriction sites and containing 6 point mutations in the ISRE of the RANTES promoter (Invitrogen) was ligated into BspEI/PflMI-digested pKC27. The oligonucleotide sequences (containing the mutations) used are as follows:

5’-CCG GAG GCT ATT TCA GTA AAC TA A ACC GTT TTG TGC AAT TTC ACT TAT GAT ACC GCC CAA TGC-3’ (forward)

5’-TTG GCC GGT ATC ATA AGT GAA ATT GCA C AA AAC GGT TTA GTT TAC TGA AAT AGC CT-3’ (reverse)

pGL2-RANTES(-181mutISRE)

This plasmid is a deletional mutant of pGL2-RANTES(900) at position -181, which also contains site-directed mutagenesis of the proximal ISRE at positions -114/113/112 bp and -109/108/107 bp (upstream of the transcriptional start site), thereby removing the ability for IRF-3 to bind at these sites. To construct this plasmid, a ~357 bp XbaI fragment containing the IRF-3 binding sites upstream of the RANTES promoter, was removed from pKC28 and cloned into XbaI-digested pGL2-RANTES(-181).
APPENDIX C: Published Manuscript


I contributed to the following publication by generating the adenoviral constructs containing the wildtype and mutant murine HA-ACTN4 sequence (AdACTN4-wt/mut) used in the study. Generation of these vectors involved several cloning steps: transfection and rescue of the Ad vectors on 293 cells, preparation of large scale virus culture (3L spinner flasks), vector purification by cesium chloride buoyant density centrifugation, and analysis of vector quality and quantity.
FSGS-associated α-actinin-4 (K256E) impairs cytoskeletal dynamics in podocytes

J-LR Michaud1,2, KM Chaisson1,3, RJ Parks1,3 and CRJ Kennedy1,2

1Kidney Research Centre and Molecular Medicine Program, Ottawa Health Research Institute, University of Ottawa, Ottawa, Ontario, Canada; 2Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario, Canada and 3Department of Biochemistry Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada

Focal segmental glomerulosclerosis (FSGS) is a common glomerular lesion and a significant cause of end-stage renal disease.1,2 Clinically, FSGS patients present with variable levels of proteinuria and a progressive loss of renal function. Pathologically, FSGS is characterized by segmental sclerosis in a proportion of glomeruli, the filtering units of the kidney.3 Accumulating evidence suggests that defects in podocytes initiate processes leading to the degeneration of filtration integrity and the development of sclerotic lesions.4,4

Podocytes are terminally differentiated cells that line the outer aspects of the glomerular capillaries.5 The highly ordered podocyte architecture consists of a cell body from which emerge major processes, which branch into foot processes that interdigitate with those of neighboring podocytes to provide the structural platform upon which a molecular sieve is formed. The foot processes are endowed with a microfilament-based contractile apparatus composed of actin, myosin-II, α-actinin, talin, paxillin, and vinculin,6 and are anchored to the glomerular basement membrane via an α5β1-integrin complex.7,8 The intricate morphology of the podocyte, coupled to its exposure to distensile forces within the glomerular capillary render these cells susceptible to damage in many nephropathies, including FSGS.

The actin bundling α-actinins are members of the spectrin superfamily. Four isoforms have been described (α-actinin-1 to -4).13 While α-actinins-2 and -3 are expressed at the Z-line of striated muscle, α-actinins-1 and -4 are more ubiquitously expressed. α-Actinin-4 is expressed in podocytes and is thought to play a key role in the maintenance of this cell's architecture.14 The putative function of α-actinin-4, which exists as a head-to-tail homodimer, is to crosslink actin filaments through its N-terminal actin-binding domain comprised of two calponin homology domains. Increasing evidence suggests that α-actinin-4 may interact with a number of other proteins such as β1-integrin,13,15,16 synaptopodin,17 vinculin,18 and phosphatidylinositol 3-kinase.19 In addition to an actin-binding domain, a number of other functional domains are found in the α-actinin-4 sequence — including two calcium-binding EF hands, a phosphoinositide-binding domain, as well as a focal adhesion kinase (FAK) tyrosine phosphorylation consensus sequence. Accordingly, phosphorylation by FAK19,20 binding of phosphoinositides,21,22
and sensitivity to intracellular calcium may modulate the actin-binding properties and localization of α-actinin following various environmental stimuli.

Mutations in the ACTN4 gene (K228E, T232I, and S235P) are associated with an autosomal-dominant form of FSGS. We developed a mouse model of ACTN4-associated FSGS by expressing the murine correlate of the K228E mutation (K256E) in a podocyte-specific manner using the mNPHS1 promoter. These mice exhibit significant proteinuria and develop FSGS-like lesions, confirming that the disease originates in the podocyte. However, the mechanism by which mutations in α-actinin-4 dysregulate podocyte function is not fully understood. Abrogation of α-actinin-4 expression in mice yields severe glomerular disease. Furthermore, recent studies by Yao et al. suggest that the familial mutations promote α-actinin-4 aggregation and thereby target the protein for degradation via the proteasome pathway, resulting in a partial loss-of-function. In contrast, mutations in α-actinin-4 increase its affinity for filamentous actin (F-actin), suggesting a gain-of-function mechanism. In support of the latter mechanism, the severity of the FSGS-like phenotype correlates directly with K256E α-actinin-4 levels in transgenic mice. Thus, it remains unclear whether and how these two viewpoints can be reconciled.

To address this issue, we assessed the functional consequences of an FSGS-associated mutation (K256E) in α-actinin-4 at the cellular level. We now report the intracellular mislocalization of K256E α-actinin-4 in mouse podocytes, which undermines the processes of cell spreading and migration, and impairs the formation of actin-rich peripheral projections. Our data suggest that such defects in key cytoskeletal-associated processes may compromise the podocyte’s ability to cope with the demands of the glomerular environment, maintain foot processes structure, and thereby initiate the progression towards sclerosis.

RESULTS
Mislocalization of K256E α-actinin-4 in cultured podocytes
Mutations in α-actinin-4 increase its affinity for F-actin in vitro. However, the subcellular localization of mutant α-actinin-4 is not clearly defined. We therefore generated adenoviral constructs with hemagglutinin (HA)-tagged wild-type or K256E α-actinin-4 and transduced a conditionally immortalized mouse podocyte cell line. Podocytes were infected with a range of virus to determine a concentration yielding efficient expression (Figure 1a). For all subsequent experiments, infections were performed with a multiplicity of infection (MOI) of 25 and incubated for 72 h. There was no apparent degradation of heterologously expressed K256E α-actinin-4 during this timeframe as its expression paralleled that of the wild-type protein (Figure 1a). As shown in Figure 1b, wild-type α-actinin-4 localized predominantly with cortical actin. The wild-type protein was also distributed along stress fibers and at focal adhesions, as identified by vinculin co-immunofluorescence (Figure 1c). Conversely, K256E α-actinin-4 was absent from the cell periphery, but was preferentially associated with stress fibers (Figure 1b) and focal adhesions (Figure 1c).

Differential association of K256E α-actinin-4 with intracellular actin pools
We next performed cellular fractionation experiments to determine the association of wild-type and K256E α-actinin-4 with various intracellular actin pools. Podocytes expressing wild-type or K256E α-actinin-4 were lyzed in Triton X-100-containing buffer and subject to differential centrifugation. As shown in Figure 2a and b, only 16.0 ± 2.5% of the wild-type α-actinin-4 associated with large cytoskeletal structures (Triton X-100 insoluble (TI) fraction), whereas 71.4 ± 5.5% of the protein remained soluble (Triton X-100 soluble (TS):S fraction). Conversely, 81.0 ± 9.6% of the K256E α-actinin-4 was associated with large cytoskeletal structures (TI fraction), and only 4.9 ± 3.4% of the mutant protein remained soluble (TS:S fraction). Expression of both wild-type and K256E α-actinin-4 was similar, as evidenced by the input. Furthermore, neither the expression of wild-type nor K256E α-actinin-4 altered total actin levels. These data reveal a differential association of wild-type versus K256E α-actinin-4, with K256E α-actinin-4 sequestered to large cytoskeletal structures such as actin bundles, whereas wild-type α-actinin-4 remains predominantly soluble.

Effect of K256E α-actinin-4 expression on cell adhesion, spreading, and migration
The inappropriate association of K256E α-actinin-4 with the actin cytoskeleton suggested that it may negatively affect cytoskeletal dynamics. We therefore determined its effect on cytoskeletal-dependent processes, such as cell adhesion, spreading, and migration. Since α-actinin-4 is associated with focal adhesions, we hypothesized that the mutant protein may negatively affect the ability of cells to adhere to an extracellular matrix. Adhesion assays were performed using podocytes expressing green fluorescent protein (GFP) alone (control), wild-type α-actinin-4, or K256E α-actinin-4 measuring their ability to bind to collagen-I-coated wells (Figure 3). The number of adherent cells was quantified at measuring various time points (3–24 h). Irrespective of the time allowed for adhesion, there was no difference in adhesion between wild-type and K256E α-actinin-4-expressing podocytes, suggesting that cell-matrix interactions are not adversely affected by K256E α-actinin-4.

We next performed a replating assay to assess the ability of cells expressing either wild-type or K256E α-actinin-4 to efficiently spread on an extracellular matrix (collagen-I). Podocytes expressing GFP alone (control), wild-type, or K256E α-actinin-4 were harvested and replated onto collagen-I-coated glass coverslips. Adherent cells were fixed after 3 or 6 h and visualized by immunofluorescence. Within 3 h of replating, a significant number of podocytes had adhered to the substratum and had begun to spread. For each condition, we observed no differences in the total number of
**Figure 1** | Subcellular localization of wild-type and K256E α-actinin-4 in mouse podocytes. (a) Differentiated podocytes were incubated with a range of adenoviral doses (multiplicity of infection 0-50) for wild-type or K256E α-actinin-4 to determine optimal infection conditions. The expression achieved with both adenoviruses was similar for each condition. (b) 3 days following infection with viruses, differentiated podocytes were fixed and stained with an anti-HA tag antibody to detect α-actinin-4 and Alexa Fluor 488-phalloidin to detect F-actin. Uninfected cells were treated in the same manner and serve as control. Wild-type α-actinin-4 is predominantly found with membrane-associated cortical actin and process-like projections with limited expression along stress fibers. Conversely, K256E α-actinin-4 is predominantly associated with stress fibers and is excluded from the cell periphery. (c) Wild-type and K256E α-actinin-4 were colocalized with vinculin at focal adhesion complexes.

**Figure 2** | Distribution of wild-type and K256E α-actinin-4 among intracellular actin pools. At 3 days post-infection, differentiated mouse podocytes were lysed in buffer containing 1% Triton X-100 and centrifuged at 15,000 g to pellet the TI fraction containing large cytoskeletal structures such as actin bundles. The TS fraction was further centrifuged at 100,000 g to separate G-actin (supernatant, S) from F-actin (pellet, P). Samples were then analyzed by Western blot using an anti-HA tag antibody and an anti-actin antibody. (a) A representative blot and (b) the graphical representation of three separate experiments illustrate the distribution of α-actinin-4 among the various actin pools. The majority (71.4±5.5%) of wild-type α-actinin-4 remained soluble (S, TS fraction), whereas the majority (81.0±9.6%) of K256E α-actinin-4 was associated with actin bundles (TI fraction). Uninfected cells were treated in the same manner and serve as control. Input lanes (Inp.) show similar expression levels of both wild-type and K256E α-actinin-4. *P < 0.005 vs wild type (n = 3).

Podocytes adhering to the extracellular matrix. However, at both time points examined, the number of spreading podocytes was significantly lower in K256E α-actinin-4-expressing cells (13.0±0.3% at 3 h; 17.3±1.0% at 6 h) compared to control (29.2±5.8% at 3 h; 37.7±5.2% at 6 h) and wild type (34.7±4.4% at 3 h; 38.4±5.8% at 6 h) (Figure 4a). Within 6 h of replating, wild-type α-actinin-4 was localized with cortical actin at the cell periphery (Figure 4b). Conversely, K256E α-actinin-4 remained associated with F-actin and condensed in the cell body (Figure 4b), consistent with the observed impairment in cell spreading.

Cell migration relies upon a dynamic cytoskeleton. The increased affinity of K256E α-actinin-4 for F-actin could undermine this process. We therefore performed haptotactic transwell migration assays to determine the effect of K256E α-actinin-4 on cell migration. Podocytes expressing GFP alone (control), wild-type, or K256E α-actinin-4 were plated onto the upper surface of transwell inserts. After 24 h, the cells remaining in the upper chamber were removed and the cells that had migrated to the underside of the insert were quantified. Podocytes expressing wild-type α-actinin-4 migrated at a similar rate (90.8±9.2%) to control cells.
**Figure 3** Effect of α-actinin-4 on podocyte adhesion. Differentiated mouse podocytes expressing either GFP alone (control), wild-type, or K256E α-actinin-4 were trypsinized and replated onto collagen-I-coated 96-well U-bottom plates at a density of 5 x 10^4 cells/well. Cells were fixed with paraformaldehyde at various time points, stained with crystal violet, and the absorbance of each well measured at 595 nm with a spectrophotometric plate reader. At every time point examined, there was no significant difference in the ability of wild-type or K256E α-actinin-4-expressing cells to adhere to an extracellular matrix. Data are from three separate experiments (n = 3) and are expressed as a percent of control for each time point.

Conversely, the migration of podocytes expressing K256E α-actinin-4 was significantly reduced (52.1 ± 10.7%; P < 0.01 vs control and wild type). These data suggest that K256E α-actinin-4 causes defects in cytoskeletal dynamics and impairs cellular processes such as spreading and migration.

**Quantification of peripheral projections in cultured podocytes**

Podocyte-specific expression of K256E α-actinin-4 leads to podocyte damage and foot process effacement *in vivo*.

The conditionally immortalized podocyte cell line used in the present studies have been shown to form foot process-like peripheral projections when cultured under non-permissive conditions. We therefore assessed the effect of K256E α-actinin-4 on peripheral projections in differentiated podocytes (Figure 6). Podocytes expressing wild-type α-actinin-4 displayed a slight increase in the mean number of projections (3.8 ± 0.8 projections/cell vs 2.9 ± 0.6 for control), whereas podocytes expressing K256E α-actinin-4 exhibited a decrease in the mean number of projections (1.9 ± 0.4) (Figure 6b). Wild-type but not K256E α-actinin-4 was readily detected in the peripheral projections, along with actin (Figure 6a). Furthermore, projections emerging from podocytes expressing wild-type α-actinin-4 appeared longer and thinner than those of control and K256E α-actinin-4-expressing podocytes. These data provide evidence that α-actinin-4 plays a key role in the formation and/or maintenance of peripheral projections in cultured podocytes.

**DISCUSSION**

We previously developed a mouse model of an inherited form of FSGS by expressing a mutant variant of α-actinin-4 (K256E) under the control of a podocyte-specific promoter (mNPHS1). In this model, approximately 50% of mice develop FSGS-like lesions and display podocyte foot process effacement. However, the direct consequences of mutant α-actinin-4 on podocyte structure and function remained unclear. We therefore assessed the effects of K256E α-actinin-4 on the cytoskeletal dynamics of cultured podocytes.

The conditionally immortalized podocyte cell line used in this study has previously been described in detail. These cells are relatively resistant to conventional transfection approaches for achieving heterologous expression of proteins. We therefore developed adenoviruses for both wild-type and K256E α-actinin-4, which yielded significant...
expression in a high proportion of cells (90%), rendering the cell population much more homogeneous than previously attained. The expression level of both wild-type and mutant K256E \(\alpha\)-actinin-4 were similar (Figure 1a), suggesting that the mutant protein is not subject to degradation in these cells.

The most impressive feature upon expression of K256E \(\alpha\)-actinin-4 is its distinct intracellular localization. Although the putative function of \(\alpha\)-actinin-4 is that of an actin crosslinking protein, we found that the majority of wild-type \(\alpha\)-actinin-4 colocalized with membrane-associated cortical actin (Figure 1b) or was detected in the TS pool (Figure 2). In contrast, K256E \(\alpha\)-actinin-4 was consistently found along stress fibers and was retained in the TI fraction (Figure 2). This sequestration is likely a direct effect of the increased affinity of K256E \(\alpha\)-actinin-4 for F-actin, and is consistent with a gain-of-function effect of such mutations. In support of this, an alternative splice variant of \(\alpha\)-actinin-4 has been reported in small-cell lung cancer. The splice variant contains three missense mutations in exon 8, the region containing FSGS-associated mutations. This mutant isoform also displays increased affinity for actin, and was found to colocalize mainly with actin stress fibers, unlike the wild-type protein, which was concentrated along the periphery of the cell.

Several reports have identified an association of actinin isoforms with components of focal adhesion complexes, such as the \(\beta_1\)-integrin subunit and vinculin.\(^{13}\) Phosphoinositides may also bind to \(\alpha\)-actinin and regulate its interaction with actin filaments or integrin receptors.\(^{21,22}\) Furthermore, \(\alpha\)-actinin is phosphorylated by FAK in platelets,\(^{20}\) reducing its cosedimentation with actin filaments. These findings clearly indicate a role for \(\alpha\)-actinin in mediating signals that could modulate the assembly of focal adhesions or the cytoskeleton. It is therefore interesting to speculate that mutations in \(\alpha\)-actinin-4, which increase its affinity for actin, may render the protein insensitive to these factors and thereby perturb cytoskeletal dynamics.

The mislocalization of mutant \(\alpha\)-actinin-4 led us to investigate its effects on cytoskeletal-dependent processes such as cell adhesion, spreading, and migration. Although we did not observe a significant impact of K256E \(\alpha\)-actinin-4 on podocyte adhesion (i.e., adhesion and replating assays), we found that it significantly affected spreading and migration. Indeed, podocytes expressing K256E \(\alpha\)-actinin-4 remained rounded and showed severe defects in their ability to spread on collagen-I. This phenotype is reminiscent of that reported in FAK-deficient embryonic mesodermal cells,\(^{31}\) which can

---

**Figure 5** Effect of \(\alpha\)-actinin-4 on podocyte migration. Differentiated mouse podocytes expressing GFP alone (control), wild-type, or K256E \(\alpha\)-actinin-4 were trypsinized and replated onto the upper surface of transwell inserts. After 3 h, the cells remaining in the upper chamber were removed and the cells on the lower surface were stained with 4',6-diamidino-2-phenylindole and counted. K256E \(\alpha\)-actinin-4 caused a 48% reduction in the number of migrating cells compared to control and wild type. \(*P < 0.01\) vs control and wild type (\(n = 5\)).

**Figure 6** Effect of \(\alpha\)-actinin-4 on peripheral projections of podocytes. At 3 days following infection with viruses for wild-type or K256E \(\alpha\)-actinin-4, differentiated podocytes were fixed and stained with an anti-HA tag antibody to detect \(\alpha\)-actinin-4 and Alexa Fluor 488-phalloidin to detect F-actin. Images in (a) are representative of cells for each condition and demonstrate actin-rich projections (arrows) emanating from the cell body. (b) Expression of wild-type \(\alpha\)-actinin-4 caused an increase in the mean number of projections \((3.8 \pm 0.8\) projections/cell vs \(2.9 \pm 0.6\) for control), whereas expression of K256E \(\alpha\)-actinin-4 caused a decrease in the number of projections \((1.9 \pm 0.4)\). \(*P < 0.05\) vs control \((n = 4)\).
adhere but fail to spread effectively on ECM, suggesting that FAK signaling may be impaired in cells expressing mutant α-actinin-4. Furthermore, as indicated by the present study, podocytes expressing K256E α-actinin-4 exhibit severe motility defects. These findings are in accordance with a role of actinin-4 in cell motility and cancer invasion, where cytoplasmic localization of α-actinin-4 is associated with an infiltrative phenotype in breast cancer cells, whereas cells with nuclear α-actinin-4 are non-invasive. Our results show that α-actinin-4 is significantly involved in cell spreading and migration. The motility deficit seen in cells expressing K256E α-actinin-4 is likely owing to the sequestering of the protein to centrally located actin stress fibers, and away from motility-based structures at the cell’s periphery.

Expression of wild-type α-actinin-4 increased the mean number of actin filament-containing peripheral projections emanating from the cell body, reminiscent of podocyte foot processes in vivo. In contrast, K256E α-actinin-4 reduced the mean number of such projections (Figure 6). Although the arborized phenotype observed in cultured podocytes is not nearly as extensive as that seen in podocytes in vivo, our data suggest that owing to mislocalization, K256E α-actinin-4 does not provide a suitable framework for the maintenance/formation of such projections. We previously showed that podocyte-specific expression of K256E α-actinin-4 leads to foot process effacement and glomerulosclerosis. Such damage may be explained by mislocalization of mutant α-actinin-4, rendering it unresponsive to appropriate signals (e.g., actin remodeling) or unable to provide structural support at the cell membrane, and thereby contribute to foot process effacement.

A recent study by Yao et al. attributes podocyte defects encountered in ACTN4-associated FSGS to a loss-of-function as mutations render α-actinin-4 more susceptible to forming unstable aggregates, which are rapidly degraded via the proteasome pathway. Conversely, in transgenic mice expressing an FSGS-associated mutant α-actinin-4, podocyte damage and sclerosis correlate directly with mutant transgene expression, consistent with a gain-of-function mechanism. We did not observe any degradation of exogenous K256E α-actinin-4 in cultured podocytes (Figure 1a) within the experimental timeframe. In light of these findings, we favor a synthesis of the two models to explain the dysregulated phenotype of podocytes expressing FSGS-associated mutant α-actinin-4. Gain-of-affinity mutations in α-actinin-4, coupled with some degradation of the mutant protein, could each contribute to a loss-of-function by effectively eliminating this protein from select intracellular locales (e.g., motility-based actin structures and process-like peripheral projections), thereby disturbing cytoskeletal-dependent processes such as cell spreading, migration, and importantly, process maintenance/formation. In support of this hypothesis, dysregulation of the actin cytoskeleton and α-actinin-4 expression/localization has been reported in various glomerular disease models characterized by podocyte foot process effacement, and is therefore likely to be a key event in the progression of podocyte injury.

In summary, we have further defined the functional consequences of an FSGS-associated form of the actin-crosslinking protein – K256E α-actinin-4. Whereas wild-type α-actinin-4 is predominantly localized to membrane-associated cortical actin in conditionally immortalized podocytes, K256E α-actinin-4 remains tightly associated with stress fibers. Mislocalization of K256E α-actinin-4 causes severe defects in motility, including cell spreading and migration. Furthermore, K256E α-actinin-4 caused a decrease in the number of foot process-like peripheral projections. Our data therefore suggest that dysregulation of the podocyte cytoskeleton may play a key role in the progression of sclerotic lesions resulting from various podocyte injuries.

MATERIALS AND METHODS

Adenoviral constructs

Adenoviral constructs containing wild-type or K256E murine HA-ACTN4 sequences were generated by subcloning from the previously described pcDNA3-HA-ACTN4 vectors. In these viruses, the HA-ACTN4 expression cassette replaced the E1-region and transcription is directed rightward, relative to the conventional human adenovirus serotype 5 map. The E1-deleted, first-generation Adenovirus vectors used in these studies were constructed using a combination of conventional cloning techniques and RecA-mediated recombination, and were grown and titered on 293 cells, as described previously.

Cell culture

Conditionally immortalized mouse podocytes were cultured on collagen-I-coated dishes in RPMI-1640 supplemented with 10% fetal bovine serum, 100 U/ml of penicillin, 100 μg/ml of streptomycin, 100 μg/ml of Normocin (InvivoGen, San Diego, CA, USA), and 10 U/ml γ-interferon (Sigma, Oakville, Ontario, Canada) at 33°C (permissive conditions). For differentiation, cells were cultured at 38°C without γ-interferon (non-permissive conditions) for at least 10 days. Cells used for experiments were between passages 5 and 15 only. Differentiated podocytes were infected with a range of viral loads (multiplicity of infection between 0 and 50 plaque-forming units/cell) to determine optimal infection conditions. Lysates (10 μg total protein) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Immunoblots were incubated with a monoclonal anti-HA antibody (HA-7, Sigma, 1:1000), followed by a horseradish peroxidase-conjugated secondary antibody and detected using Supersignal West Pico Chemiluminescence (Pierce, Rockford, IL, USA). Immunoblots were stripped and reprobed with an anti-actin antibody (Sigma, 1:1000). For all subsequent experiments, differentiated podocytes were infected at a multiplicity of infection of 25 plaque-forming units/cell and incubated for 72 h to achieve sufficient protein expression.

Fluorescence microscopy

At 3 days post-infection, podocytes grown on collagen-coated coverslips were processed for immunofluorescence. Cells were fixed with 4% paraformaldehyde, washed with phosphate-buffered saline (PBS), permeabilized with 0.2% Triton X-100, blocked with 2% bovine serum albumin, and incubated with an anti-HA tag antibody.
Fractionation of intracellular actin pools
Infected differentiated mouse podocytes were scraped into ice-cold lysis buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1 mM ethyleneglycol tetraacetate, 1 mM ethylenediaminetetraacetic acid, 1% Triton X-100, 0.5% Nonidet P-40) supplemented with protease inhibitor cocktail (Sigma, 1:100) and phenylmethylsulfonyl fluoride, and incubated at room temperature for 15 min. Cell lysates were then centrifuged at 15,000 g to isolate the T fractions. The TS fraction was removed and further centrifuged at 100,000 g to separate G-actin (supernatant, S) and F-actin (pellet, P). All pellets were resuspended in the original sample volume. A small aliquot of the total lysate was reserved for protein determination using a Bicinchoninic Acid Protein Assay Kit (Pierce). Samples of equal volume (10 μg total protein in lysate) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The membranes were probed with a polyclonal anti-HA tag antibody (Clontech, Palo Alto, CA, USA, 1:1000) followed by a horseradish peroxidase-conjugated secondary antibody and developed using Supersignal West Pico Chemiluminescent Substrate (Pierce). The immunoblots were subsequently stripped and reprobed with an anti-actin antibody (Sigma, 1:1000). The membranes were exposed to film, images were scanned with a Hewlett Packard ScanJet 6000C, and densitometry of the bands measured using Kodak 1D 3.5 software.

Cell adhesion assays
Differentiated mouse podocytes, having been infected with adenovirus 72 h earlier, were harvested by trypsin/ethylenediaminetetraacetic acid treatment, centrifuged, and resuspended in RPMI containing 10% fetal bovine serum and counted with a hemacytometer. Cells were seeded onto collagen-I-coated U-bottom 96-well plates (5 x 10^4 cells/well) and incubated at 38°C. At various times following replating, the wells were washed with PBS, and adherent cells fixed with 4% paraformaldehyde and processed for immunofluorescence as described above (Fluorescence microscopy). Peripheral projections emanating from the cell body of HA-positive cells were quantified by counting 4,6-diamidino-2-phenylindole-stained nuclei. Data are from five experiments expressed as the percentage of control.

Statistics
Values reported are the means ± s.e.m. from at least three experiments. Statistical comparisons were made using unpaired t-test or one-way analysis of variance followed by the Newman-Keuls multiple comparison test.

ACKNOWLEDGMENTS
We are grateful to Peter Mundel (Albert Einstein, New York) for the conditionally immortalized podocyte cell line. Robin J Parks is supported by the Canadian Institutes of Health Research (CIHR), CIHR/Muscular Dystrophy Association of Canada/Amyotrophic Lateral Sclerosis Society of Canada Partnership Grant, Premier’s Research Excellence Award, and the Jesse Davidson Foundation for Gene and Cell Therapy. CRJ Kennedy and RJ Parks are CIHR New Investigator Awardees. Jean-Louis R Michaud is a recipient of a CIHR Doctoral Award. This work is supported by an operating grant from the Kidney Foundation of Canada.

REFERENCES
Koralee Chaisson

246 First Ave. Apt#2
Ottawa, ON K1S 2G6
613-799-1530
kchai093@uottawa.ca

EDUCATION

2004 - 2007 \textit{The University of Ottawa, Ottawa, ON}
\textbf{Master of Science}
Department of Biochemistry, Microbiology and Immunology

2000 - 2004 \textit{Mount Allison University, Sackville, NB}
\textbf{Bachelor of Science, Honours Biochemistry}
Department of Biology and Biochemistry

1997 - 2000 Colonel Gray Senior High School, Charlottetown, PEI
\textbf{Formal Education}

EMPLOYMENT

2004 - 2006 \textit{The University of Ottawa, Ottawa, ON}
\textbf{MSc. Thesis Project, Department of Biochemistry, Microbiology and Immunology}
\textit{Supervisor:} Dr. Robin Parks
\textit{Title:} Interferon Regulatory Factor-3 Activation in Adenovirus Infection

Techniques used: SDS-PAGE, western blotting, immunoprecipitation, cell culture, transient transfection of cell cultures, luciferase assays for protein expression, design and construction of plasmid and viral vectors, bacterial transformation, viral titering, DNA/RNA/protein isolation and quantitation, agarose gel electrophoresis, RT-PCR, PCR, immunofluorescence, microscopy.

05/2004 - 06/2004 \textit{Mount Allison University, Sackville, NB}
\textbf{Research Assistant, Department of Biology and Biochemistry}
\textit{Supervisor:} Dr. Suzanne Currie

Assisted with lab maintenance, chemical inventory, and data entry.
BSc. Honours Thesis Project, Department of Biology and Biochemistry

Supervisor: Dr. Suzanne Currie

Title: Does temperature affect susceptibility of juvenile rainbow trout (Oncorhynchus mykiss) to endocrine disruption?

Investigated the role of temperature and heat shock proteins in the mechanism of endocrine disruption in juvenile rainbow trout exposed to the estrogen mimic 4-nonylphenol.

Techniques used: isolation of fish tissues, protein extraction and quantitation, SDS-PAGE, western blotting, ELISA, Gas Chromatography Mass Spectroscopy.

Teaching Assistant, Department of Biology and Biochemistry

Lab demonstrator for first, second, and third year undergraduate biology and biochemistry labs. Responsibilities included: teaching basic laboratory skills and marking lab assignments.

Research Student, Crops and Livestock Research Center

Supervisor: Dr. Rick Peters

2002 - Investigated the effect of seafood waste as an organic amendment on the soil borne pathogen Rhizoctonia solani (a potato fungus)

2001- Assisted Dr. Peters in various research projects concerning the control of soil borne diseases in potatoes.

Skills acquired: sterile technique, bacterial and fungal isolation and culturing, bacterial identification using the MIDI system (volatile fatty-acid fingerprinting via Gas Chromatography), DNA extraction, PCR, basic laboratory skills.

AWARDS

- 2005-2007 Ontario Graduate Scholarship ($15000/yr)
- 2005-2007 University of Ottawa Excellence Scholarship ($5535, $4386)
- 2005-2006 University of Ottawa Student Bursary ($1500)
- 2003 NSERC Undergraduate Research Award ($5750)
- 2002-2004 Dean’s List, Mount Allison University
- 2000-2001 Mount Allison University Entrance Scholarship ($1000)
DISTINCTIONS

- 2005  Third prize poster presentation, University of Ottawa, Dept. of Microbiology and Immunology Annual Poster Day ($50)
- 2004  Third prize poster presentation, Atlantic Undergraduate Universities Biology Conference, University College of Cape Breton ($75)
- 2003  Lady H. E. Banting Prize, Mount Allison University ($100)

PUBLICATION


CONFERENCE PRESENTATIONS

Chaisson, K.M., and S. Currie, *Does 4-Nonylphenol Cause Endocrine Disruption in Juvenile Rainbow Trout?* Atlantic Undergraduate Universities Biology Conference, University College of Cape Breton, Sydney, NS, March 2004